US20060142252A1 - Tubulin binding agents and corresponding prodrug constructs - Google Patents
Tubulin binding agents and corresponding prodrug constructs Download PDFInfo
- Publication number
- US20060142252A1 US20060142252A1 US11/359,095 US35909506A US2006142252A1 US 20060142252 A1 US20060142252 A1 US 20060142252A1 US 35909506 A US35909506 A US 35909506A US 2006142252 A1 US2006142252 A1 US 2006142252A1
- Authority
- US
- United States
- Prior art keywords
- compound
- phosphate
- covalent bond
- group
- tubulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004243 Tubulin Human genes 0.000 title claims abstract description 52
- 108090000704 Tubulin Proteins 0.000 title claims abstract description 52
- 239000000651 prodrug Substances 0.000 title abstract description 37
- 229940002612 prodrug Drugs 0.000 title abstract description 37
- 239000011230 binding agent Substances 0.000 title abstract description 27
- 210000005166 vasculature Anatomy 0.000 claims abstract description 21
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 77
- 206010028980 Neoplasm Diseases 0.000 claims description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 229910019142 PO4 Inorganic materials 0.000 claims description 34
- 239000010452 phosphate Substances 0.000 claims description 32
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 25
- 230000002062 proliferating effect Effects 0.000 claims description 25
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 230000002792 vascular Effects 0.000 claims description 21
- 150000001412 amines Chemical class 0.000 claims description 13
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 13
- 230000017531 blood circulation Effects 0.000 claims description 12
- 230000003211 malignant effect Effects 0.000 claims description 12
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 12
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 claims description 11
- 230000001613 neoplastic effect Effects 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 208000037803 restenosis Diseases 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000001028 anti-proliverative effect Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 230000017074 necrotic cell death Effects 0.000 claims description 5
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 2
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 2
- 201000000159 corneal neovascularization Diseases 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 5
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012692 Diabetic uveitis Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 6
- 230000008685 targeting Effects 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 abstract description 4
- 125000005418 aryl aryl group Chemical group 0.000 abstract description 2
- 150000008298 phosphoramidates Chemical class 0.000 abstract description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003014 phosphoric acid esters Chemical class 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 67
- 239000000243 solution Substances 0.000 description 50
- 239000000203 mixture Substances 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical class C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 24
- 235000021317 phosphate Nutrition 0.000 description 24
- -1 hydroxyl-substituted tetralone Chemical class 0.000 description 22
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 0 [1*]C.[2*]C1=C([3*])C([4*])=C([5*])C2=C1c([Y])(CC1=CC=CC=C1)c([8*])-c([7*])c2[6*] Chemical compound [1*]C.[2*]C1=C([3*])C([4*])=C([5*])C2=C1c([Y])(CC1=CC=CC=C1)c([8*])-c([7*])c2[6*] 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- 239000004066 vascular targeting agent Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical group C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- KTIKLRGFDKNYST-UHFFFAOYSA-N 6-methoxy-7-nitro-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=C(OC)C([N+]([O-])=O)=C2 KTIKLRGFDKNYST-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 210000004688 microtubule Anatomy 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000004679 31P NMR spectroscopy Methods 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 102000029749 Microtubule Human genes 0.000 description 7
- 108091022875 Microtubule Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 229960005527 combretastatin A-4 phosphate Drugs 0.000 description 6
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- SUFDFKRJYKNTFH-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydronaphthalene Chemical compound C1CCCC2=CC(OC)=CC=C21 SUFDFKRJYKNTFH-UHFFFAOYSA-N 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- FZVSKXGLSBHYDG-UHFFFAOYSA-N (4-acetyloxy-3-methoxy-8-oxo-6,7-dihydro-5h-naphthalen-2-yl) acetate Chemical compound O=C1CCCC2=C(OC(C)=O)C(OC)=C(OC(C)=O)C=C21 FZVSKXGLSBHYDG-UHFFFAOYSA-N 0.000 description 4
- KVJWCFCHDPZOQF-UHFFFAOYSA-N 6-methoxy-5-nitro-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=C([N+]([O-])=O)C(OC)=CC=C21 KVJWCFCHDPZOQF-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000002137 anti-vascular effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000001177 diphosphate Substances 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 4
- 235000011180 diphosphates Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- MGOGKPMIZGEGOZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanamide Chemical group OC[C@H](N)C(N)=O MGOGKPMIZGEGOZ-REOHCLBHSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- XAOOZMATJDXDQJ-UHFFFAOYSA-N 5-bromo-1,2,3-trimethoxybenzene Chemical compound COC1=CC(Br)=CC(OC)=C1OC XAOOZMATJDXDQJ-UHFFFAOYSA-N 0.000 description 3
- DRGYBSPEFZKVIT-UHFFFAOYSA-N 5-hydroxy-6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=C(O)C(OC)=CC=C21 DRGYBSPEFZKVIT-UHFFFAOYSA-N 0.000 description 3
- JXUDZDMWQXSPPF-UHFFFAOYSA-N 7-hydroxy-6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=C(OC)C(O)=C2 JXUDZDMWQXSPPF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000024248 Vascular System injury Diseases 0.000 description 3
- 208000012339 Vascular injury Diseases 0.000 description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004155 blood-retinal barrier Anatomy 0.000 description 3
- 230000004378 blood-retinal barrier Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- KYURVEFXWRAYDD-UHFFFAOYSA-N lithium;1,2,3-trimethoxybenzene-5-ide Chemical compound [Li+].COC1=C[C-]=CC(OC)=C1OC KYURVEFXWRAYDD-UHFFFAOYSA-N 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- TVZQDMRKJSXJPZ-UHFFFAOYSA-N 1,2-dihydronaphthalen-1-ol Chemical class C1=CC=C2C(O)CC=CC2=C1 TVZQDMRKJSXJPZ-UHFFFAOYSA-N 0.000 description 2
- JRHUABJPULIQRA-UHFFFAOYSA-N 2,2-dihydroxy-3,4-dihydronaphthalen-1-one Chemical class C1=CC=C2C(=O)C(O)(O)CCC2=C1 JRHUABJPULIQRA-UHFFFAOYSA-N 0.000 description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 2
- MKAJNQGWJAFIBW-UHFFFAOYSA-N 2-methoxy-5-(3,4,5-trimethoxyphenyl)-7,8-dihydronaphthalen-1-amine Chemical compound C=1CCC2=C(N)C(OC)=CC=C2C=1C1=CC(OC)=C(OC)C(OC)=C1 MKAJNQGWJAFIBW-UHFFFAOYSA-N 0.000 description 2
- MQFKJLHUAJQVFR-UHFFFAOYSA-N 3-[tert-butyl(dimethyl)silyl]oxy-2-methoxy-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CCCC2=C1C(O)=C(OC)C(O[Si](C)(C)C(C)(C)C)=C2 MQFKJLHUAJQVFR-UHFFFAOYSA-N 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
- LGKLBBJBGJFPDN-UHFFFAOYSA-N 5,7-dihydroxy-6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=C(O)C(OC)=C(O)C=C21 LGKLBBJBGJFPDN-UHFFFAOYSA-N 0.000 description 2
- DEYFWGXTPWNADC-UHFFFAOYSA-N 6-[2-phenylethyl(propyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol Chemical class C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CC=C1 DEYFWGXTPWNADC-UHFFFAOYSA-N 0.000 description 2
- MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 2
- WTLLPCDWXACECD-UHFFFAOYSA-N 6-methoxy-5-nitro-1-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2h-naphthalen-1-ol Chemical compound [O-][N+](=O)C=1C(OC)=CC=C2C=1CCCC2(O)C1=CC(OC)=C(OC)C(OC)=C1 WTLLPCDWXACECD-UHFFFAOYSA-N 0.000 description 2
- PIEHNLLZVQVCCJ-UHFFFAOYSA-N 7-amino-6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=C(OC)C(N)=C2 PIEHNLLZVQVCCJ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- HDFFVHSMHLDSLO-UHFFFAOYSA-N Dibenzyl phosphate Chemical class C=1C=CC=CC=1COP(=O)(O)OCC1=CC=CC=C1 HDFFVHSMHLDSLO-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000002125 Hemangioendothelioma Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108091077621 MAPRE family Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 150000004814 combretastatins Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- VXNQMUVMEIGUJW-XNOMRPDFSA-L disodium;[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound [Na+].[Na+].C1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 VXNQMUVMEIGUJW-XNOMRPDFSA-L 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000013171 endarterectomy Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000011630 iodine Chemical group 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002790 naphthalenes Chemical class 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000027498 negative regulation of mitosis Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000250 revascularization Effects 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N trans-stilbene Chemical compound C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 231100000513 vascular toxicity Toxicity 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UZZZDORLBZBJHV-UHFFFAOYSA-N (2-methoxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetate Chemical compound C1CCCC2=C(OC(C)=O)C(OC)=CC=C21 UZZZDORLBZBJHV-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- CMJGVUDRUQIJRS-UHFFFAOYSA-N (4-acetyloxy-3-methoxy-5,6,7,8-tetrahydronaphthalen-2-yl) acetate Chemical compound C1CCCC2=C(OC(C)=O)C(OC)=C(OC(C)=O)C=C21 CMJGVUDRUQIJRS-UHFFFAOYSA-N 0.000 description 1
- JAAJQSRLGAYGKZ-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-ol Chemical class C1=CC=C2C(O)CCCC2=C1 JAAJQSRLGAYGKZ-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical compound C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JDEJRLXMWUYMSS-UHFFFAOYSA-N 2-(2-phenylethenyl)-1h-quinazolin-4-one Chemical class N1C2=CC=CC=C2C(=O)N=C1C=CC1=CC=CC=C1 JDEJRLXMWUYMSS-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- VFICBAHRMYIJHL-UHFFFAOYSA-N 7-[tert-butyl(dimethyl)silyl]oxy-6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=C1C=C(OC)C(O[Si](C)(C)C(C)(C)C)=C2 VFICBAHRMYIJHL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 101100482081 Agrobacterium vitis (strain S4 / ATCC BAA-846) iaaM gene Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 1
- 101100170834 Arabidopsis thaliana ERDJ3A gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OBLOLPISIXMHLW-UHFFFAOYSA-L COC1=CC(C2=CCCC3=C2C=CC(OC)=C3OP(=O)([O-])[O-])=CC(OC)=C1OC.[Na+].[Na+] Chemical compound COC1=CC(C2=CCCC3=C2C=CC(OC)=C3OP(=O)([O-])[O-])=CC(OC)=C1OC.[Na+].[Na+] OBLOLPISIXMHLW-UHFFFAOYSA-L 0.000 description 1
- XEFRNCLPPFDWAC-UHFFFAOYSA-N COc1cc(N)cc(OC)c1OC Chemical compound COc1cc(N)cc(OC)c1OC XEFRNCLPPFDWAC-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 244000253759 Carya myristiciformis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- LUEYTMPPCOCKBX-UHFFFAOYSA-N Curacin A Natural products C=CCC(OC)CCC(C)=CC=CCCC=CC1CSC(C2C(C2)C)=N1 LUEYTMPPCOCKBX-UHFFFAOYSA-N 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N Curacin A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101100110004 Homo sapiens PYCARD gene Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 235000014072 Juglans neotropica Nutrition 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100095608 Mus musculus Serinc3 gene Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007135 Retinal Neovascularization Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- AQZZSWZMWUUVCI-UHFFFAOYSA-M benzenediazonium;hydrogen sulfate Chemical compound OS([O-])(=O)=O.N#[N+]C1=CC=CC=C1 AQZZSWZMWUUVCI-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- PJANXHGTPQOBST-QXMHVHEDSA-N cis-stilbene Chemical class C=1C=CC=CC=1/C=C\C1=CC=CC=C1 PJANXHGTPQOBST-QXMHVHEDSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(I) oxide Inorganic materials [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 1
- SXTLQDJHRPXDSB-UHFFFAOYSA-N copper;dinitrate;trihydrate Chemical compound O.O.O.[Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O SXTLQDJHRPXDSB-UHFFFAOYSA-N 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940112669 cuprous oxide Drugs 0.000 description 1
- KRFJLUBVMFXRPN-UHFFFAOYSA-N cuprous oxide Chemical compound [O-2].[Cu+].[Cu+] KRFJLUBVMFXRPN-UHFFFAOYSA-N 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 1
- 108010045524 dolastatin 10 Proteins 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 238000002003 electron diffraction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000000893 fibroproliferative effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003879 microtubule-organizing center Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CKMCMIZAFKDKAN-UHFFFAOYSA-N naphthalene;phosphoric acid Chemical class OP(O)(O)=O.C1=CC=CC2=CC=CC=C21 CKMCMIZAFKDKAN-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RQKYHDHLEMEVDR-UHFFFAOYSA-N oxo-bis(phenylmethoxy)phosphanium Chemical compound C=1C=CC=CC=1CO[P+](=O)OCC1=CC=CC=C1 RQKYHDHLEMEVDR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- NRKFVEPAQNCYNJ-YGGCHVFLSA-J tetrasodium;[3-methoxy-2-phosphonatooxy-6-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P(=O)([O-])OC1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 NRKFVEPAQNCYNJ-YGGCHVFLSA-J 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 101150116154 tms1 gene Proteins 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N trans-Stilbene Natural products C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/94—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
- C07C223/06—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
- C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
- C07C45/512—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being a free hydroxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/18—Esters of thiophosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/247—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
- C07F9/655354—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the cytoskeletal protein tubulin is among the most attractive therapeutic drug targets for the treatment of solid tumors.
- a particularly successful class of chemotherapeutics mediates its anti-tumor effect through a direct binding interaction with tubulin.
- This clinically promising class of therapeutics, called Tubulin Binding Agents exhibit potent tumor cell cytotoxicity by efficiently inhibiting the polymerization of ⁇ -tubulin heterodimers into the microtubule structures that are required to facilitate mitosis or cell division (Hamel, Medicinal Research Reviews, 1996).
- Vinca Alkaloids such as Vinblastine and Vincristine (Owellen et al, Cancer Res., 1976; Lavielle et al, J. Med. Chem., 1991) along with Taxanes such Taxol (Kingston, J. Nat. Prod., 1990; Schiff et al, Nature, 1979; Swindell et al, J. Cell Biol., 1981).
- natural products such as Rhizoxin (Nakada et al, Tetrahedron Lett., 1993; Boger et al, J. Org.
- tubulin Binding Agents exploit the relatively rapid mitosis that occurs in proliferating tumor cells. By binding to tubulin and inhibiting the formation of the spindle apparatus in a tumor cell, the Tubulin Binding Agent can cause significant tumor cell cytotoxicity with relatively minor effects on the slowly dividing normal cells of the patient.
- tubulin binding site interactions remain largely unknown, and they definitely vary between each class of Tubulin Binding Agent.
- Photoaffinity labeling and other binding site elucidation techniques have identified three key binding sites on tubulin: 1) the Colchicine site (Floyd et al, Biochemistry, 1989; Staretz et al, J. Org. Chem., 1993; Williams et al, J. Biol. Chem., 1985; Wolff et al, Proc. Natl. Acad. Sci.
- the present invention addresses this urgent need by providing a structurally novel class of Tubulin Binding Agent compositions with potent antiproliferative activity and tumor cell cytotoxicity.
- the present invention provides the important discovery that corresponding prodrug constructs of these agents have selective effects on the tumor vasculature that are independent of any antimitotic effect on the cells of the tumor. These agents are capable of selectively shutting down the flow of blood to a tumor and causing secondary tumor cell death.
- the present compositions have expanded clinical utility over known tubulin binding agents.
- the present invention relates to a discovery of dihydronaphthalene compounds that result from the judicious combination of a non-tubulin binding molecular template which, when suitably modified with structural features such as hydroxyl moieties and arylalkoxy groups, are found to function as Tubulin Binding Agents capable of inhibiting tubulin polymerization and tumor cell proliferation.
- the present invention focuses on dihydronaphthalene derivatives, particularly compounds of the following general Formula Ia: wherein:
- a particularly preferred dihydronaphthalene derivative is the compound of the following structure (1):
- the invention contemplates methods of contacting a tubulin-containing system with an effective amount of a compound of Formula I. Methods are also provided for treating a warm-blooded animal afflicted with a neoplastic disease comprising administering an effective amount of compound capable of inhibiting the proliferation of the neoplastic disease.
- the antiproliferative effect has the direct result of causing tumor cell cytotoxicity due to inhibition of mitosis.
- the invention broadly contemplates the provision of a method for treating a warm-blooded animal having a vascular proliferative disorder comprising administering an effective amount of a compound of the present invention to achieve targeted vascular toxicity at a locality of proliferating vasculature, wherein in the proliferating vasculature is malignant or nonmalignant.
- the invention broadly contemplates the provision of a method for administering an effective amount of a compound of the present invention to selectively reduce the flow of blood to at least a portion of a neoplastic region, thereby causing substantial necrosis of tissue in the neoplastic region without substantial necrosis of tissue in adjoining regions.
- the effect of reduced tumor blood flow is reversible so that normal tumor blood flow is restored following cessation of treatment.
- FIG. 1 illustrates a synthetic route for large-scale preparation of starting material required for synthesis of tubulin binding agents.
- FIG. 2 illustrates a synthetic route for the preparation of an exemplary hydroxyl-substituted tetralone.
- FIG. 3 illustrates a synthetic route for the preparation of an exemplary dihydroxy-substituted tetralone.
- FIG. 4 illustrates a synthetic route for the preparation of exemplary amine-substituted tetralones.
- FIG. 5 A depicts exemplary aryl-substituted dihydronaphthalene tubulin binding agents and; and B) amine, aryl-substituted dihydronaphthalene and tetrahydronaphthalene tubulin binding agents and corresponding prodrug constructs.
- FIG. 6 A depicts exemplary hydroxyl, aryl-substituted dihydronaphthalene and tetrahydronaphthalene tubulin binding agents; and B) corresponding prodrug constructs.
- FIG. 7 A depicts exemplary aroyl-substituted dihydronaphthalene tubulin binding agents and corresponding prodrug constructs; B) an exemplary aroyl-substituted naphthalene prodrug construct.
- FIG. 8 illustrates a general synthetic route for the preparation of aryl-substituted dihydronaphthalene and tetrahydronaphthalene tubulin binding agents.
- FIG. 9 illustrates a synthetic route for the preparation of an exemplary amine, aryl-substituted dihydronaphthalene and its corresponding phosphoramidate prodrug.
- FIG. 10 illustrates a synthetic route for the preparation of an exemplary hydroxyl, aryl-substituted dihydronaphthalene tubulin binding agent.
- FIG. 11 illustrates a synthetic route for the preparation of an exemplary hydroxyl, aryl-substituted dihydronaphthalene tubulin binding agent and its corresponding phosphate prodrug.
- FIG. 12 illustrates a synthetic route for the preparation of an exemplary aroyl-substituted dihydronaphthalene, its corresponding phosphate prodrug, and an exemplary aroyl-substituted naphthalene phosphate prodrug.
- FIG. 13 illustrates a synthetic route for the preparation of an exemplary dihydroxy, aryl-substituted dihydronaphthalene tubulin binding agent and its corresponding diphosphate prodrug.
- FIG. 14 illustrate a synthetic route for the preparation of exemplary diaryl-substituted dihydronaphthalene compositions.
- the compounds of the present invention demonstrate remarkable cytotoxicity against a variety of human cancer cell lines.
- the ability of an agent to inhibit tubulin polymerization and microtubule formation is an important property of many anticancer agents. Disruption of microtubules that comprise the cytoskeleton and mitotic spindle apparatus can interfere dramatically with the ability of a cell to successfully complete cell division.
- the compounds of the present invention are highly cytotoxic to actively proliferating cells, inhibiting their mitoic division and often causing their selective apoptosis while leaving normal quiescent cells relatively unaffected.
- VTAs Vascular Targeting Agents
- Angiogenesis is characterized by the proliferation of tumor endothelial cells and generation of new vasculature to support the growth of a tumor.
- VEGF Vascular Endothelial Growth Factor
- anti-angiogenic strategies have been developed to inhibit this signaling process at one or more steps in the biochemical pathway in order to prevent the growth and establishment of the tumor vasculature.
- anti-angiogenic therapies act slowly and must be chronically administered over a period of months to years in order to produce a desired effect.
- VTAs In contrast to anti-angiogenic agents, VTAs attack solid tumors by selectively targeting the established tumor vasculature and causing extensive shutdown of tumor blood flow. A single dose of a VTA can cause a rapid and selective shutdown of the tumor neovasculature within a period of minutes to hours, leading eventually to tumor necrosis by induction of hypoxia and nutrient depletion. This vascular-mediated cytotoxic mechanism of VTA action is quite divorced from that of anti-angiogenic agents that inhibit the formation of new tumor vascularization, rather than interfering with the existing tumor vasculature. Other agents have been known to disrupt tumor vasculature but differ in that they also manifest substantial normal tissue toxicity at their maximum tolerated dose.
- CA4DP Combretastatin A-4 Disodium Phosphate Prodrug
- Tubulin binding VTAs that have been discovered include the Colchicinoid ZD6126 (Davis et al., Cancer Research, 2002 ) and the Combretastatin analog AVE8032 (Lejeune et al, Proceedings of the AACR., 2002). It is thought that tubulin-binding VTAs selectively destabilize the microtubule cytoskeleton of tumor endothelial cells, causing a profound alteration in the shape of the cell which ultimately leads to occlusion of the tumor blood vessel and shutdown of blood flow to the tumor (Kanthou, Blood, 2002).
- VTAs vascular targeting agents
- the present invention is directed to the administration of a vascular targeting agent (“VTA”), particularly a tubulin binding VTA, for the treatment of malignant or non-malignant vascular proliferative disorders in ocular tissue.
- VTA vascular targeting agent
- Neovascularization of ocular tissue is a pathogenic condition characterized by vascular proliferation and occurs in a variety of ocular diseases with varying degrees of vision failure.
- the administration of a VTA for the pharmacological control of the neovascularization associated with non-malignant vascular proliferative disorders such as wet macular degeneration, proliferative diabetic retinopathy or retinopathy of prematurity would potentially benefit patients for which few therapeutic options are available.
- the invention provides the administration of a VTA for the pharmacological control of neovascularization associated with malignant vascular proliferative disorders such as ocular tumors.
- the blood-retinal barrier is composed of specialized nonfenestrated tightly-joined endothelial cells that form a transport barrier for certain substances between the retinal capillaries and the retinal tissue.
- the nascent vessels of the cornea and retina associated with the retinopathies are aberrant, much like the vessels associated with solid tumors.
- Tubulin binding agents, inhibitors of tubulin polymerization and vascular targeting agents may be able to attack the aberrant vessels because these vessels do not share architectural similarities with the blood retinal barrier.
- Tubulin binding agents may halt the progression of the disease much like they do with a tumor-vasculature.
- the compounds of the present invention are also contemplated for use in the treatment of vascular disease, particularly atherosclerosis and restenosis.
- Atherosclerosis is the most common form of vascular disease and leads to insufficient blood supply to critical body organs, resulting in heart attack, stroke, and kidney failure. Additionally, atherosclerosis causes major complications in those suffering from hypertension and diabetes, as well as tobacco smokers.
- Atherosclerosis is a form of chronic vascular injury in which some of the normal vascular smooth muscle cells (“VSMC”) in the artery wall, which ordinarily control vascular tone regulating blood flow, change their nature and develop “cancer-like” behavior.
- VSMC normal vascular smooth muscle cells
- VSMC become abnormally proliferative, secreting substances (growth factors, tissue-degradation enzymes and other proteins) which enable them to invade and spread into the inner vessel lining, blocking blood flow and making that vessel abnormally susceptible to being completely blocked by local blood clotting, resulting in the death of the tissue served by that artery.
- Restenosis is due to a complex series of fibroproliferative responses to vascular injury involving potent growth-regulatory molecules, including platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), also common to the later stages in atherosclerotic lesions, resulting in vascular smooth muscle cell proliferation, migration and neointimal accumulation.
- PDGF platelet-derived growth factor
- bFGF basic fibroblast growth factor
- Restenosis occurs after coronary artery bypass surgery (CAB), endarterectomy, and heart transplantation, and particularly after heart balloon angioplasty, atherectomy, laser ablation or endovascular stenting (in each of which one-third of patients redevelop artery-blockage (restenosis) by 6 months), and is responsible for recurrence of symptoms (or death), often requiring repeat revascularization surgery.
- CAB coronary artery bypass surgery
- atherectomy laser ablation or endovascular stenting
- endovascular stenting in each of which one-third of patients redevelop artery-blockage (restenosis) by 6 months
- recurrence of symptoms or death
- amino acid acyl group in the amino acid acylamino group is an acyl group derived from the amino acid.
- the amino acids may be enumerated by ⁇ -amino acids, ⁇ -amino acids and ⁇ -amino acids.
- preferred amino acids include glycine, alanine, leucine, serine, lysine, glutamic acid, asparatic acid, threonine, valine, isoleucine, ornithine, glutamine, asparagines, tyrosine, phenylalanine, cysteine, methionine, arginine, ⁇ -alanine, tryptophan, proline, histidine, etc.
- the preferred amino acid is serine and the preferred amino acid acyl group is a serinamide.
- “Amine” refers to a free amine NH 2 or a lower alkylamino.
- Animal refers to any warm-blooded mammal, preferably a human.
- Alkyl refers to a group containing from 1 to 8 carbon atoms and may be straight chained or branched.
- An alkyl group is an optionally substituted straight, branched or cyclic saturated hydrocarbon group.
- alkyl groups may be substituted with up to four substituent groups, R as defined, at any available point of attachment.
- R substituent groups
- Exemplary unsubstituted such groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like.
- substituents may include but are not limited to one or more of the following groups: halo (such as F, Cl, Br, I), haloalkyl (such as CCl 3 or CF 3 ), alkoxy, alkylthio, hydroxy, carboxy (—COOH), alkyloxycarbonyl (—C(O)R), alkylcarbonyloxy (—OCOR), amino (—NH 2 ), carbamoyl (—NHCOOR— or —OCONHR—), urea (—NHCONHR—) or thiol (—SH).
- Alkyl groups as defined may also comprise one or more carbon to carbon double bonds or one or more carbon to carbon triple bonds.
- Aryl refers to groups with aromaticity, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, as well as multicyclic systems with at least one aromatic ring.
- aryl groups include benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
- the aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, etc.
- the preferred aryl group of the present invention is a benzene ring.
- “Aroyl” refers to the —(C ⁇ O)-aryl groups, wherein aryl is defined as hereinabove.
- the aryl group is bonded to the core compound through a carbonyl bridge.
- Cycloalkyl is a species of alkyl containing from 3 to 15 carbon atoms, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings. Exemplary unsubstituted such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, etc. Exemplary substituents include one or more of the following groups: halogen, alkyl, alkoxy, alkyl hydroxy, amino, nitro, cyano, thiol and/or alkylthio.
- Halogen or “Halo” refers to chlorine, bromine, fluorine or iodine.
- “Lower alkoxy” refers to —O-alkyl groups, wherein alkyl is as defined hereinabove.
- the alkoxy group is bonded to the core compound through the oxygen bridge.
- the alkoxy group may be straight chained or branched; although the straight-chain is preferred. Examples include methoxy, ethyloxy, propoxy, butyloxy, t-butyloxy, i-propoxy, and the like.
- Preferred alkoxy groups contain 1-4 carbon atoms, especially preferred alkoxy groups contain 1-3 carbon atoms. The most preferred alkoxy group is methoxy.
- “Lower alkylamino” refers to a group wherein one or two alkyl groups is bonded to an amino nitrogen, i.e., NH(alkyl).
- the nitrogen is the bridge connecting the alkyl group the core compound. Examples include NHMe, NHEt, NHPr, and the like.
- Prodrug refers to a precursor form of the drug which is metabolically converted in vivo to produce the active drug.
- Preferred prodrugs of the present invention include the phosphate, phosphoramidate, or amino acid acyl groups as defined herein.
- the phosphate ester salt moiety may also include (—OP(O)(O-alkyl) 2 or (—OP(O)(O—NH 4 + ) 2 ).
- Phenolic moiety means herein a hydroxy group when it refers to an R group on an aryl ring.
- Phosphate “Phosphate moiety”, or “Phosphate prodrug salt” refers to phosphate ester salt moiety (—OP(O)(O ⁇ M + ) 2 ), a phosphate triester moiety (—OP(O)(OR) 2 ) or a phosphate diester moiety (—OP(O)(OR)(O ⁇ M + ), where M is a salt and R is chosen to be any appropriate alkyl or branched alkyl substituent (the two R groups may be the same alkyl group or may be mixed), or benzyl, or aryl groups.
- the salt M is advantageously Na, K and Li, but the invention is not limited in this respect.
- Phosphoramidate refers to a phosphoamidate ester salt moiety (—NP(O)(O ⁇ M + ) 2 ), a phosphoramidate diester moiety (—NP(O)(OR) 2 ), or a phosphamidate disalt moiety (—NP(O)(OR)(O ⁇ M + ), where M is a salt and R is chosen to be any appropriate alkyl or branched alkyl substituent (the two R groups may be the same alkyl group or may be mixed), or benzyl, or aryl groups.
- the salt M is advantageously Na, K and Li, but the invention is not limited in this respect.
- Salt is a pharmaceutically acceptable salt and can include acid addition salts such as the hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, and tartrates; alkali metal cations such as Na, K, Li, alkali earth metal salts such as Mg or Ca or organic amine salts such as those disclosed in PCT International Application Nos. WO02/22626 or WO00/48606.
- Tubulin Binding Agent shall refer to a ligand of tubulin or a compound capable of binding to either ⁇ -tubulin heterodimers or microtubules and interfering with the polymerization or depolymerization of microtubules.
- Tumors “Tumors”, “Cancers”, or “Neoplastic Disease” shall be used interchangeably and include (but are not limited to) the following:
- Vascular toxicity refers to the selective destruction, damage, or occlusion, whether reversible or irreversible, partial or complete, of proliferating vasculature.
- Malignant proliferating vasculature refers to the endothelium, artery, blood vessel, or neovasculature formed by a malignant disease state, such as a tumor.
- Nonmalignant proliferating vasculature refers to the endothelium, artery, blood vessel, or neovasculature formed by undesirable or pathological angiogenesis and that is associated with disease states other than a malignant disease state, including without limitation ocular diseases such wet or age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, diabetic molecular edema, uveitis, and corneal neovascularization, or other nonocular disease states such as psoriasis, rheumatoid arthritis, atheroma, restenosis, Kaposi's sarcoma, haemangioma, and in general, inflammatory diseases characterized by vascular proliferation.
- ocular diseases such wet or age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, diabetic molecular edema, uveitis, and corneal neovascularization
- Antiproliferative or “antimitotic” refer to the ability of the compounds of the present invention to directly inhibit the proliferation of tumor cells and impart direct cytotoxicity towards tumor cells.
- Treating includes its generally accepted meaning which encompasses prohibiting, preventing, restraining, and slowing, stopping, or reversing progression, severity, of a resultant symptom. As such, the methods of this invention encompass both therapeutic and prophylactic administration.
- Effective amount refers to the amount or dose of the compound, upon single or multiple dose administration to the patient, which provides the desired effect in the patient under diagnosis or treatment.
- an effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances.
- determining the effective amount or dose of compound administered a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
- a typical daily dose will contain from about 0.1 mg/kg to about 1000 mg/kg of the active compound of this invention. Preferably, daily doses will be about 10 mg/kg to about 100 mg/kg, and most preferably about 10 mg.
- a compound of the present invention can be administered systemically in any form or mode which makes the compound bioavailable in effective amounts.
- Systemic administration may be accomplished by administration of a compound of the present invention into the bloodstream at a site which is separated by a measurable distance from the diseased or affected organ or tissue.
- compounds of the present invention can be administered orally, parenterally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, buccally, and the like.
- Oral or intravenous administration is generally preferred for treating neoplastic disease or cancer.
- the compound may be administered non-systemically by local administration of the compound of the present invention directly at the diseased or affected organ or tissue.
- Treatment of ocular diseases characterized by the presence of non-malignant proliferative vasculature or neovascularization can be achieved using non-systemic administration methods such as intravitreal injection, sub-Tenon's injection, ophthalmic drops, iontophoresis, topical formulation and implants and/or inserts.
- non-systemic administration methods such as intravitreal injection, sub-Tenon's injection, ophthalmic drops, iontophoresis, topical formulation and implants and/or inserts.
- One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the disease state to be treated, the stage of the disease, and other relevant circumstances.
- the present invention provides a pharmaceutical composition, which comprises a compound of the present invention or a pharmaceutically acceptable salt thereof as defined hereinabove and a pharmaceutically acceptable diluent or carrier.
- compositions are prepared by known procedures using well-known and readily available ingredients.
- the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may be in the form of a capsule, sachet, paper, or other container.
- the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments containing, for example, up to 10% by weight of active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- Suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragcanth, gelatin, calcium silicate, micro-crystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil.
- the formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents.
- Compositions of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well know in the art.
- compositions are preferably formulated in a unite dosage form, each dosage containing from about 1 mg to about 500 mg, more preferably about 5 mg to about 300 mg (for example 25 mg) of the active ingredient.
- unit dosage form refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient.
- suitable pharmaceutical carrier diluent, or excipient.
- compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers.
- the active compounds of the invention may be formulated for oral, buccal, transdermal (e.g., patch), intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.
- the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose of calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate).
- binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g., lactose, microcrystalline cellulose of calcium phosphate
- lubricants e.g., magnesium stearate, talc or silica
- disintegrants e.g., potato starch or
- Liquid preparations for oral administration may take the form, of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
- suspending agents e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats
- emulsifying agents e.g., lecithin or acacia
- non-aqueous vehicles e.g., almond oil, oily esters or ethyl alcohol
- composition may take the form of tablets or lozenges formulated in conventional manner.
- the active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion.
- Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative.
- the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in a powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- the active compounds of the invention are conveniently delivered in the form of a solution or suspension form a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the pressurized container or nebulizer may contain a solution or suspension of the active compound.
- Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
- Tablets or capsules of the compounds may be administered singly or two or more at a time as appropriate. It is also possible to administer the compounds in sustained release formulations.
- the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient.
- the above dosages are exemplary of the average case. There can of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
- the compounds of the present invention can be administered by inhalation or in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder.
- An alternative means of transdermal administration is by use of a skin patch.
- they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin. They can also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilizers an preservatives as may be required.
- administering means any of the standard methods of administering a compound to a subject, known to those skilled in the art. Examples include, but are not limited to intravenous, intramuscular or intraperitoneal administration.
- the clonogenic toxicity may be increased by imbalancing Ca 2+ cytosolic levels or nucleotide pools or in combination thereof.
- “pharmaceutically acceptable carriers” means any of the standard pharmaceutical carriers.
- suitable carriers are well known in the art and may-include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solutions phosphate buffered saline containing POLYSORB 80, water, emulsions such as oilwater emulsion, and various type of wetting agents.
- Other carrier may also include sterile solutions, tablets, coated tablets, and capsules.
- Such carriers typically contain excipients such as starch, milk, sugar, certain types of clay gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums glycols, or other known excipients.
- excipients such as starch, milk, sugar, certain types of clay gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums glycols, or other known excipients.
- Such carriers may also include flavor and color additives or other ingredients.
- Compositions comprising such carriers are formulated by well known convention methods.
- the starting alcohol was absent (or nearly so) by TLC, and the mixture was filtered through a 3-cm pad of silica gel, rinsing well with dichloromethane.
- the mud-brown solution was concentrated by distillation on a rotary evaporator followed by aspirator vacuum to yield an opaque brown liquid.
- This was purified in 30 mL portions by Kugelrohr distillation ( ⁇ 0.5 Torr, 140° C.) to yield 104.4 g of a brown liquid which crystallized on brief standing. This was dissolved in hot hexanes (104 mL) and filtered hot through Celite to yield a clear yellow solution. This was seeded and left in a refrigerator ( ⁇ 5° C.) overnight.
- the crystalline product was filtered cold, washed quickly with a small amount of cold hexanes and dried under pump vacuum to give 84.8 g (303 mol, 58% yield from isovanillin) recrystallized light yellow solid, pure by 1 H and 13 C NMR.
- a second crop of crystals (6.3 g) were obtained by dissolving the concentrated filtrate in hot hexanes (20 mL) followed by seeding and standing overnight.
- An important part of the present invention is a new efficient method of converting 3-TBSO-4-methoxyacetophenone (3) to ⁇ -halo-3-TBSO-4-methoxyacetophenone (5) by treatment of the trimethylsilyl enol ether (4) [1-(3-TBSO-4-methoxyphenyl)-1-trimethylsiloxy(TMSO)-ethylene] with elemental halogen.
- Bromine is the preferred halogen. It is understood that chlorine and iodine may be utilized in place of bromine should iodo or chloro analogs be desired.
- a fundamental intermediate in the synthesis of the compounds of the present invention is a substituted tetralone structure (see FIG. 8 ).
- a procedure for the synthesis of mono-hydroxy substituted tetralone from tetrahydronaphthalene is illustrated with an exemplary synthetic route in FIG. 2 .
- a mixture of 6-methoxy-1,2,3,4-tetrahydronaphthalene (6) and TMEDA was treated with sec-butyllithium at room temperature followed by addition of trimethyl borate.
- the resultant mixture was subsequently treated with acetic acid and 35% hydrogen peroxide to form the hydroxytetrahydronaphthalenes 7 and 8 which are easily separated by column chromatography.
- the 5-hydroxy isomer 7 was converted to 5-acetoxy-6-methoxy-1,2,3,4-tetrahydronaphthalene (9) in 95% yield. Reaction of the 9 with DDQ in dioxane-water led to the formation of tetralone 10 as a single isomer in 96 % yield. The correct position of the keto group was confirmed by single-crystal X-ray crystallography. The acetate was removed by treating tetralone 10 with sodium bicarbonate in methanol to form 5-hydroxy-6-methoxy-1-tetralone (11).
- the invention provides the synthesis di-hydroxytetralones as intermediates.
- the synthesis of an exemplary dihydroxy tetralone is provided in FIG. 3 .
- 5,7-dihydroxy-6-methoxy-1-tetralone (19) is synthesized by protection of the 7-hydroxy group in the tetrahydronaphthalene 17 as its corresponding TBS ether (13) proceeded in high yield.
- TBS ether 1,3-dihydroxy-6-methoxy-1-tetralone
- a procedure for the synthesis of mono-amino substituted tetralone from tetrahydronaphthalene is illustrated with an exemplary synthetic route in FIG. 4 .
- 6-methoxy-1-tetralone (20, 17.6 g, 0.10 mol) in acetone (30 mL) was added dropwise a mixture of sulfuric acid (18 mL, 96.0%) and nitric acid (15 mL, 68.0-70.0%). After the addition was complete, the reaction was stirred at 0° C. for 6 hours, and TLC was employed to monitor the reaction progress.
- Hydroxy-functionalized tetralones were also obtained from amino-functionalized counterpart. For example, 23 (0.96 g, 5.0 mol) was dissolved in a mixture of sulfuric acid (96%, 2.1 mL) and H 2 O (3.9 mL). The solution was cooled to 0 C, and ice (5.0 g) was added resulting in the crystallization of a solid. A solution of NaNO 2 (0.48 g, 7 mol) in H 2 O (5 mL) was added dropwise at 0° C., After the solution had been stirred for an additional 10 min, a few crystals of urea were added to decompose any excess sodium nitrite.
- cupric nitrate trihydrate (19.0 g, 78.6 mol) in H 2 O (150 mL) at 0° C.
- cuprous oxide (0.72 g, 5.0 mol) was added to the solution.
- the solution was stirred for 10 more min, and TLC was employed to monitor the reaction.
- the mixture was partitioned between ethyl ether and water. The organic layer was dried over anhydrous sodium sulfate, and after filtration, the organic layer was concentrated in vacuo to provide (12) as a yellow oil.
- Each aryl-substituted compound was synthesized according the generalized synthetic scheme illustrated in FIG. 8 .
- Amine, Aryl-substituted dihydronaphthelene compounds and their corresponding prodrugs are contemplated as part of the invention. Exemplary compounds are depicted in FIG. 5 .
- the C-5 amine dihydronaphthalene derivative, Oxi-com 142 (31), and its phosphoramidate prodrug Oxi-com 143 (32) were synthesized as illustrated in FIG. 9 .
- 6-Methoxy-5-nitro-1-tetralone (21) (2.65 g, 12.0 mol) was added at ⁇ 20 ° C. to the trimethoxyphenyllithium and stirring was continued for 2 h ( ⁇ 20° C.—RT).
- the mixture was partitioned between CH 2 Cl 2 and water, the organic layer was dried over anhydrous sodium sulfate, and, after filtration, the organic layer was concentrated in vacuo, to afford 1-Hydroxy-6-methoxy-5-nitro-1-(3′,4′,5′-trimethoxyphenyl)tetralin (30) as a crude yellow oil. (GC-MS shows the yield is about 55%).
- L-serinamide prodrug derivative of 31 was obtained by dissolving 3,4-dihydro-5-FMOC-L-serinamide-6-methoxy-1-(3′,4′,5′-trimethoxyphenyl) naphthalene (0.0435 g, 0.0679 mmol) in CH 2 Cl 2 (1.2 mL) and CH 3 OH (1.2 mL). While stirring, NaOH (0.003 g, 0.000075 mmol) was added and allowed to react at room temperature for 16 h.
- Dihydronaphthalene compounds functionalized with hydroxy groups are contemplated in the present invention. Exemplary compounds are depicted in FIG. 6A .
- the exemplary C-7 hydroxy-dihydronaphthalene analog Oxi-com 158 (36) was synthesized based on the synthetic pathway illustrated in FIG. 10 .
- Phosphate Prodrugs in the form of phosphate salts and esters of hydroxyl functionalized dihydronaphthalene derivatives (and related phenolic analogs) are envisioned, for example phosphate ester disodium salts of C-5 (Oxi-com 197, 43) and C-7 Dihydronaphthalene (42) as illustrated in FIG. 6B .
- phosphate ester disodium salts of C-5 (Oxi-com 197, 43) and C-7 Dihydronaphthalene (42) as illustrated in FIG. 6B .
- the phenol Oxi-com 196 (37) was converted to its disodium phosphate prodrug salt using by sequential treatment of CCl4, iPr2Net, DMAP, and dibenzylphosphite in acetonitrole to produce the dibenzyl phosphate derivative (46) in 86% yield.
- the dibenzyl phosphate derivative was then stirred with NaI and TMS1 in acetonitrile at RT for 30 min to debenzylate the compound. After removal of acetonitrile and drying, the residue was stirred overnight with NaOMe in methanol to form a salt. Crystallization in acetone-water produced the prodrug Oxi-com 197 as a white powder.
- Aryol-substituted dihydronaphthalene ligands have previously described in U.S. Pat. No. 6,162,930. Hydroxyl functionalized derivatives and corresponding phosphate prodrugs of this compound are now provided (see FIG. 7A ). A detailed synthetic route for this compound is illustrated in FIG. 12 .
- CA4P is a potent vascular targeting and destruction agent in vivo
- CA1P a diphosphate
- CA4P is enzymatically converted to CA4, which in turn interacts with tubulin to cause vascular disruption, it is reasonable to expect that the new tubulin binding ligands described herein may prove to be enhanced vascular targeting agents once functionalized as diphosphates.
- the syntheses of these compounds will parallel the methodology described in the various synthetic schemes delineated within this application and will be readily apparent to persons skilled in the art. A representative synthesis is illustrated in FIG. 13 .
- IC 50 values for tubulin polymerization were determined according to a previously described procedure (Bai et al, Cancer Research, 1996). Purified tubulin is obtained from bovine brain cells as described in Hamel and Lin (Hamel and Lin, Biochemistry, 1984). Various amounts of inhibitor were preincubated for 15 minutes at 37° C. with purified tubulin. After the incubation period, the reaction was cooled and GTP was added to induce tubulin polymerization. Polymerization was then monitored in a Gilford spectrophotometer at 350 nm.
- the final reaction mixtures (0.25 ml) contained 1.5 mg/ml tubulin, 0.6 mg/ml microtubule-associated proteins (MAPs), 0.5 mM GTP, 0.5 mM MgCl 2 , 4% DMSO and 0.1M 4-morpholineethanesulfonate buffer (MES, pH 6.4).
- IC 50 is the amount of inhibitor needed to inhibit tubulin polymerization 50% with respect to the amount of inhibition that occurs in the absence of inhibitor.
- the activity of several compounds were tested against a variety of cell lines derived from human tumors, using an assay system similar to a procedure previously described (Monks et al, J. Natl. Cancer Inst., 1991). Briefly, the cell suspensions, diluted according to the particular cell type and the expected target cell density (5,000-40,000 cells per well based on cell growth characteristics), were added by pipet (100 ⁇ l) to 96-well microtiter plates. Inoculates were allowed a preincubation time of 24-28 hours at 37° C. for stabilization. Incubation with the inhibitor compounds lasted for 48 hours in 5% CO 2 atmosphere and 100% humidity.
- Determination of cell growth was performed by in situ fixation of cells, followed by staining with a protein-binding dye sulforhodamine B (SRB), which binds to the basic amino acids of cellular macromolecules.
- SRB protein-binding dye sulforhodamine B
- ED 50 value (defined as the effective dosage required to inhibit 50% of cell growth) was measured.
- CNS central nervous system
- BXPC-3 pancreas
- NCI-H460 non-small cell lung cancer
- MCF-7 breast
- colon KM20L2
- DU-145 prostate
- IC 50 value (defined as the amount of compound required to inhibit growth of 50% of cells with respect to a control treatment) for each compound was determined at one hour and five days at (see Table 3 below).
- Table 3 In vitro Cytotoxicity against Murine cancer cell lines Compound IC 50 ( ⁇ M) at 1 hour IC 50 ( ⁇ M) at 5 days Oxi-com 196, 37 0.11 0.004 Oxi-com 197, 43 0.10 0.003 Oxi-com 199, 50 >44.8 >44.8 Oxi-com 200, 49 >50 16.2 Oxi-com 224, 47 0.4 0.003 Oxi-com 225, 48 0.4 0.005 Oxi-com 229, 33 >44 >1.4 Oxi-com 238, 38 14.0 0.04 Oxi-com 239, 44 2.4 0.06 Oxi-com 240, 39 8.0 0.03 Oxi-com 241, 45 2.5 0.08 Oxi-com 243, 46 20. 0.30
- MHEC-5T hemangioendothelioma tumor model was established by subcutaneous injection of 0.5 ⁇ 106 cultured transformed cell murine myocardial vascular endothelial cell line (“MHEC5-T”) cells into the right flank of Fox Chase CB-17 Severe Combined Immunodeficient (“SCID”) mice.
- MHEC5-T myocardial vascular endothelial cell line
- mice When transplanted tumors reached a size of 500 mm 3 (a size without development of necrosis), the mice received a single intraperitoneal (i.p.) injection of saline control or compound at doses ranging from 3.2 to 25 mg/kg.
- mice were injected intravenously with 0.25 ml of diluted FluoSphere beads (1:6 in physiological saline) in the tail vein, sacrificed after 3 minutes, and tumor was excised for cryosectioning. Tumor cryosections at a thickness of 8 um were directly examined using quantitative fluorescent microscopy. Blood vessels were indicated by blue fluorescence from injected beads.
- vascular shutdown was expressed as vessel area (mm 2 ) per tumor tissue area (mm 2 ) as a percentage of the control (“% VAPM”) and as vessel number per tumor tissue area (mm 2 ) as a percentage of the control (“% VNPM”).
- % VAPM percentage of the control
- % VNPM vessel number per tumor tissue area
- C-5 dihydronaphthalene phosphate prodrug, Oxi-com 197 was assessed in tumor-bearing mice by measuring its effects on tumor volume in comparison with CA4P.
- compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved.
- the prodrugs of the present invention would be administered at a dosage of from about 5 mg/m 2 to about 100 mg/m 2 while intravascular infusion of the prodrug is preferred other modes of parenteral topical or enteral administration are usable under certain conditions.
- the present invention also involves uses of the novel compounds described in manners relating to their useful effects on tubulin polymerization and abnormal vasculature.
- a method for inhibiting tubulin polymerization is a part of the present invention. This involves contacting a tubulin containing system with an effective amount of a compound described in the present invention.
- This tubulin containing system may be in a tumor cell, thereby inhibiting neoplastic disease by administering an effective amount of a compound of the present invention. Patients may thus be treated.
- neoplasias such as leukemia, lung cancer, colon cancer, thyroid cancer, CNS, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancers may be effectively treated by the administration of an effective amounts of the compounds described in the present invention.
- Pharmaceutical preparations may be prepared by mixing the compounds of the present invention with a pharmaceutically acceptable carrier. This may be in tablet or intravascular form.
- macular degeneration, and related diseases of the eye where vascularization is involved may be treated by a method comprising administering an effective amount of a compound described in the present invention.
- Psoriasis may also be treated by administering an effective amount of the compound of the present invention.
- any disease or condition caused or enhanced by undesired vascularization may be treated by administering an effective amount of a compound of the present invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A diverse set of tubulin binding agents have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl-aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, phosphoramidates, and other prodrugs capable of demonstrating selective targeting and destruction of tumor cell vasculature.
Description
- This is a Continuation of U.S. patent application Ser. No. 10/404,525, filed Apr. 1, 2003, which itself is a Continuation-In-Part of co-pending U.S. patent application Ser. No. 09/804,280, filed Mar. 12, 2001, which itself claims priority to U.S. provisional patent application Ser. No. 60/188,295, filed on Mar. 10, 2000. This application also claims the priority benefit of co-pending U.S. patent application Er. No. 10/218,833, filed Aug. 14, 2002, which itself claims priority to both U.S. patent application Ser. No. 09/505,402, filed Feb. 16, 2000 and U.S. provisional patent application Ser. No. 60/120,478, filed Feb. 18, 1999. Attention is called to U.S. Pat. No. 6,162,930 issued to Pinney et al. on Dec. 19, 2000, which is incorporated in pertinent part by reference herein for the reasons cited.
- The cytoskeletal protein tubulin is among the most attractive therapeutic drug targets for the treatment of solid tumors. A particularly successful class of chemotherapeutics mediates its anti-tumor effect through a direct binding interaction with tubulin. This clinically promising class of therapeutics, called Tubulin Binding Agents, exhibit potent tumor cell cytotoxicity by efficiently inhibiting the polymerization of αβ-tubulin heterodimers into the microtubule structures that are required to facilitate mitosis or cell division (Hamel, Medicinal Research Reviews, 1996).
- Currently, the most widely recognized and clinically useful antitumor agents are Vinca Alkaloids, such as Vinblastine and Vincristine (Owellen et al, Cancer Res., 1976; Lavielle et al, J. Med. Chem., 1991) along with Taxanes such Taxol (Kingston, J. Nat. Prod., 1990; Schiff et al, Nature, 1979; Swindell et al, J. Cell Biol., 1981). Additionally, natural products such as Rhizoxin (Nakada et al, Tetrahedron Lett., 1993; Boger et al, J. Org. Chem., 1992; Rao, et al, Tetrahedron Lett., 1992; Kobayashi et al, Pure Appl. Chem., 1992; Kobayashi et al, Indian J. Chem., 1993; Rao et al, Tetrahedron Lett., 1993), the Combretastatins (Lin et al, Biochemistry, 1989; Pettit et al, J. Nat. Prod., 1987; Pettit et al, J. Org. Chem., 1985; Pettit et al, Can. J. Chem., 1982; Dorr et al, Invest. New Drugs, 1996), Curacin A (Gerwick et al, J. Org. Chem., 59:1243, 1994), Podophyllotoxin (Hammonds et al, J. Med. Microbiol, 1996; Coretese et al, J. Biol. Chem., 1977), Epothilones A and B (Nicolau et al., Nature, 1997), Dolastatin-10 (Pettit et al, J. Am. Chem. Soc., 1987; Pettit et al, Anti-Cancer Drug Des., 1998), and Welwistatin (Zhang et al, Molecular Pharmacology, 1996), as well as certain synthetic analogues including Phenstatin (Pettit G R et al., J. Med. Chem., 1998), 2-styrylquinazolin-4(3H)-ones (“SQOs”, Jiang et al, J. Med. Chem., 1990), and highly oxygenated derivatives of cis- and trans-stilbene and dihydrostilbene (Cushman et al, J. Med. Chem., 1991) are all known to mediate tumor cytotoxic activity through a mode of action that includes tubulin binding and subsequent inhibition of mitosis.
- Normally, during the metaphase of cell mitosis, the nuclear membrane has broken down and tubulin is able to form centrosomes (also called microtubule organizing centers) that facilitate the formation of the microtubule spindle apparatus to which the dividing chromosomes become attached. Subsequent polymerization and depolymerization of the spindle apparatus mitigates the separation of the daughter chromosomes during anaphase such that each daughter cell contains a full complement of chromosomes. As antiproliferatives or antimitotic agents, Tubulin Binding Agents exploit the relatively rapid mitosis that occurs in proliferating tumor cells. By binding to tubulin and inhibiting the formation of the spindle apparatus in a tumor cell, the Tubulin Binding Agent can cause significant tumor cell cytotoxicity with relatively minor effects on the slowly dividing normal cells of the patient.
- The exact nature of tubulin binding site interactions remain largely unknown, and they definitely vary between each class of Tubulin Binding Agent. Photoaffinity labeling and other binding site elucidation techniques have identified three key binding sites on tubulin: 1) the Colchicine site (Floyd et al, Biochemistry, 1989; Staretz et al, J. Org. Chem., 1993; Williams et al, J. Biol. Chem., 1985; Wolff et al, Proc. Natl. Acad. Sci. U.S.A., 1991), 2) the Vinca Alkaloid site (Safa et al, Biochemistry, 1987), and 3) a site on the polymerized microtubule to which taxol binds (Rao et al, J. Natl. Cancer Inst., 1992; Lin et al, Biochemistry, 1989; Sawada et al, Bioconjugate Chem, 1993; Sawada et al, Biochem. Biophys. Res. Commun., 1991; Sawada et al, Biochem. Pharmacol., 1993). An important aspect of this work requires a detailed understanding, at the molecular level, of the “small molecule” binding domain of both the α and β subunits of tubulin. The tertiary structure of the α,β tubulin heterodimer was reported in 1998 by Downing and co-workers at a resolution of 3.7 Å using a technique known as electron crystallography (Nogales et al, Nature, 1998). This brilliant accomplishment culminates decades of work directed toward the elucidation of this structure and should facilitate the identification of small molecule binding sites, such as the colchicine site, using techniques such as photoaffinity and chemical affinity labeling (Chavan et al, Bioconjugate Chem., 1993; Hahn et al, Photochem. Photobiol., 1992).
- An aggressive chemotherapeutic strategy for the treatment and maintenance of solid tumor cancers continues to rely on the development of architecturally new and biologically more potent Tubulin Binding Agents which mediate their effect through a direct binding interaction with tubulin. The present invention addresses this urgent need by providing a structurally novel class of Tubulin Binding Agent compositions with potent antiproliferative activity and tumor cell cytotoxicity. In addition, the present invention provides the important discovery that corresponding prodrug constructs of these agents have selective effects on the tumor vasculature that are independent of any antimitotic effect on the cells of the tumor. These agents are capable of selectively shutting down the flow of blood to a tumor and causing secondary tumor cell death. Thus the present compositions have expanded clinical utility over known tubulin binding agents.
- The present invention relates to a discovery of dihydronaphthalene compounds that result from the judicious combination of a non-tubulin binding molecular template which, when suitably modified with structural features such as hydroxyl moieties and arylalkoxy groups, are found to function as Tubulin Binding Agents capable of inhibiting tubulin polymerization and tumor cell proliferation.
-
- R1 is optionally H, halogen, or lower alkoxy,
- R2 through R8 are independently selected from the group consisting of H, OH, amine, lower alkoxy, phosphate, phosphoramidate, or amino acid acyl group,
- is optionally a single covalent bond or double covalent bond,
- X is optionally a single covalent bond or a carbonyl group, and
- Y is optionally H or OH.
-
- R1a, R1b, R1c, R1d, and R1e are independently selected from the group consisting of H, halogen, or lower alkoxy,
- R2 through R6 are independently selected from the group consisting of H, OH, halogen, amine, lower alkoxy, phosphate, phosphoramidate, or amino acid acyl; and
- X is a single covalent bond or a carbonyl group.
-
-
-
- R1a, R1b, R1c, R1d, and R1e are independently selected from the group consisting of H, halogen, or lower alkoxy,
- R2 through R6 are independently selected from the group consisting of H. OH, halogen, amine, lower alkoxy, phosphate, phosphoramidate, or amino acid acyl; and
- X is a single covalent bond or a carbonyl group.
- In a second aspect, the invention contemplates methods of contacting a tubulin-containing system with an effective amount of a compound of Formula I. Methods are also provided for treating a warm-blooded animal afflicted with a neoplastic disease comprising administering an effective amount of compound capable of inhibiting the proliferation of the neoplastic disease. In a preferred embodiment, the antiproliferative effect has the direct result of causing tumor cell cytotoxicity due to inhibition of mitosis.
- In a third aspect, the invention broadly contemplates the provision of a method for treating a warm-blooded animal having a vascular proliferative disorder comprising administering an effective amount of a compound of the present invention to achieve targeted vascular toxicity at a locality of proliferating vasculature, wherein in the proliferating vasculature is malignant or nonmalignant.
- In yet another aspect, the invention broadly contemplates the provision of a method for administering an effective amount of a compound of the present invention to selectively reduce the flow of blood to at least a portion of a neoplastic region, thereby causing substantial necrosis of tissue in the neoplastic region without substantial necrosis of tissue in adjoining regions. In a preferred embodiment, the effect of reduced tumor blood flow is reversible so that normal tumor blood flow is restored following cessation of treatment.
- The details of one or more embodiments of the invention are set forth in the accompanying description below. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
-
FIG. 1 illustrates a synthetic route for large-scale preparation of starting material required for synthesis of tubulin binding agents. -
FIG. 2 illustrates a synthetic route for the preparation of an exemplary hydroxyl-substituted tetralone. -
FIG. 3 illustrates a synthetic route for the preparation of an exemplary dihydroxy-substituted tetralone. -
FIG. 4 illustrates a synthetic route for the preparation of exemplary amine-substituted tetralones. -
FIG. 5 A ) depicts exemplary aryl-substituted dihydronaphthalene tubulin binding agents and; and B) amine, aryl-substituted dihydronaphthalene and tetrahydronaphthalene tubulin binding agents and corresponding prodrug constructs. -
FIG. 6 A ) depicts exemplary hydroxyl, aryl-substituted dihydronaphthalene and tetrahydronaphthalene tubulin binding agents; and B) corresponding prodrug constructs. -
FIG. 7 A ) depicts exemplary aroyl-substituted dihydronaphthalene tubulin binding agents and corresponding prodrug constructs; B) an exemplary aroyl-substituted naphthalene prodrug construct. -
FIG. 8 illustrates a general synthetic route for the preparation of aryl-substituted dihydronaphthalene and tetrahydronaphthalene tubulin binding agents. -
FIG. 9 illustrates a synthetic route for the preparation of an exemplary amine, aryl-substituted dihydronaphthalene and its corresponding phosphoramidate prodrug. -
FIG. 10 illustrates a synthetic route for the preparation of an exemplary hydroxyl, aryl-substituted dihydronaphthalene tubulin binding agent. -
FIG. 11 illustrates a synthetic route for the preparation of an exemplary hydroxyl, aryl-substituted dihydronaphthalene tubulin binding agent and its corresponding phosphate prodrug. -
FIG. 12 illustrates a synthetic route for the preparation of an exemplary aroyl-substituted dihydronaphthalene, its corresponding phosphate prodrug, and an exemplary aroyl-substituted naphthalene phosphate prodrug. -
FIG. 13 illustrates a synthetic route for the preparation of an exemplary dihydroxy, aryl-substituted dihydronaphthalene tubulin binding agent and its corresponding diphosphate prodrug. -
FIG. 14 illustrate a synthetic route for the preparation of exemplary diaryl-substituted dihydronaphthalene compositions. - The compounds of the present invention demonstrate remarkable cytotoxicity against a variety of human cancer cell lines. The ability of an agent to inhibit tubulin polymerization and microtubule formation is an important property of many anticancer agents. Disruption of microtubules that comprise the cytoskeleton and mitotic spindle apparatus can interfere dramatically with the ability of a cell to successfully complete cell division. The compounds of the present invention are highly cytotoxic to actively proliferating cells, inhibiting their mitoic division and often causing their selective apoptosis while leaving normal quiescent cells relatively unaffected.
- Further significance is given to new drugs that bind to the colchicine site since it has recently been shown that many tubulin binding agents which bind to this site also demonstrate activity against malignant proliferating vasculature. Antivascular chemotherapy is an emerging area of cancer chemotherapy which centers on the development of drugs, called Vascular Targeting Agents (“VTAs”) or vascular damaging agents, that selectively target the vasculature of tumor cells rather than the tumor cells themselves. Much of the research in anti-vascular cancer therapy has focused on understanding the process of new blood vessel formation, known as angiogenesis, and identifying anti-angiogenic agents which inhibit the formation of new blood vessels. Angiogenesis is characterized by the proliferation of tumor endothelial cells and generation of new vasculature to support the growth of a tumor. This growth is stimulated by certain growth factors produced by the tumor itself. One of these growth factors, Vascular Endothelial Growth Factor (“VEGF”), is relatively specific towards endothelial cells, by virtue of the restricted and up-regulated expression of its cognate receptor. Various anti-angiogenic strategies have been developed to inhibit this signaling process at one or more steps in the biochemical pathway in order to prevent the growth and establishment of the tumor vasculature. However, anti-angiogenic therapies act slowly and must be chronically administered over a period of months to years in order to produce a desired effect.
- In contrast to anti-angiogenic agents, VTAs attack solid tumors by selectively targeting the established tumor vasculature and causing extensive shutdown of tumor blood flow. A single dose of a VTA can cause a rapid and selective shutdown of the tumor neovasculature within a period of minutes to hours, leading eventually to tumor necrosis by induction of hypoxia and nutrient depletion. This vascular-mediated cytotoxic mechanism of VTA action is quite divorced from that of anti-angiogenic agents that inhibit the formation of new tumor vascularization, rather than interfering with the existing tumor vasculature. Other agents have been known to disrupt tumor vasculature but differ in that they also manifest substantial normal tissue toxicity at their maximum tolerated dose. In contrast, genuine VTAs retain their vascular shutdown activity at a fraction of their maximum tolerated dose. Combretastatin A-4 Disodium Phosphate Prodrug (“CA4DP”) is the lead drug of a group of VTAs currently in clinical trials (U.S. Pat. No.5,561,122; Chaplin et al, Anticancer Res., 1999; Tozer et al, Cancer Res., 1999; Pettit and Rhodes, Anti-Cancer Drug Des., 1998; Iyer et al, Cancer Res., 1998; Dark et al, Cancer Res., 1997;; ). Other Tubulin binding VTAs that have been discovered include the Colchicinoid ZD6126 (Davis et al., Cancer Research, 2002 ) and the Combretastatin analog AVE8032 (Lejeune et al, Proceedings of the AACR., 2002). It is thought that tubulin-binding VTAs selectively destabilize the microtubule cytoskeleton of tumor endothelial cells, causing a profound alteration in the shape of the cell which ultimately leads to occlusion of the tumor blood vessel and shutdown of blood flow to the tumor (Kanthou, Blood, 2002). Thus the invention provides the discovery that the compounds of the invention as well as analogs thereof, are vascular targeting agents (VTAs), and thus are useful for the treatment of malignant vascular proliferative disorders, such as solid tumor cancers, as well as other nonmalignant vascular proliferative disorders, such as retinal neovascularization and restenosis.
- In one embodiment, the present invention is directed to the administration of a vascular targeting agent (“VTA”), particularly a tubulin binding VTA, for the treatment of malignant or non-malignant vascular proliferative disorders in ocular tissue.
- Neovascularization of ocular tissue is a pathogenic condition characterized by vascular proliferation and occurs in a variety of ocular diseases with varying degrees of vision failure. The administration of a VTA for the pharmacological control of the neovascularization associated with non-malignant vascular proliferative disorders such as wet macular degeneration, proliferative diabetic retinopathy or retinopathy of prematurity would potentially benefit patients for which few therapeutic options are available. In another embodiment, the invention provides the administration of a VTA for the pharmacological control of neovascularization associated with malignant vascular proliferative disorders such as ocular tumors.
- The blood-retinal barrier (BRB) is composed of specialized nonfenestrated tightly-joined endothelial cells that form a transport barrier for certain substances between the retinal capillaries and the retinal tissue. The nascent vessels of the cornea and retina associated with the retinopathies are aberrant, much like the vessels associated with solid tumors. Tubulin binding agents, inhibitors of tubulin polymerization and vascular targeting agents, may be able to attack the aberrant vessels because these vessels do not share architectural similarities with the blood retinal barrier. Tubulin binding agents may halt the progression of the disease much like they do with a tumor-vasculature.
- The compounds of the present invention are also contemplated for use in the treatment of vascular disease, particularly atherosclerosis and restenosis. Atherosclerosis is the most common form of vascular disease and leads to insufficient blood supply to critical body organs, resulting in heart attack, stroke, and kidney failure. Additionally, atherosclerosis causes major complications in those suffering from hypertension and diabetes, as well as tobacco smokers. Atherosclerosis is a form of chronic vascular injury in which some of the normal vascular smooth muscle cells (“VSMC”) in the artery wall, which ordinarily control vascular tone regulating blood flow, change their nature and develop “cancer-like” behavior. These VSMC become abnormally proliferative, secreting substances (growth factors, tissue-degradation enzymes and other proteins) which enable them to invade and spread into the inner vessel lining, blocking blood flow and making that vessel abnormally susceptible to being completely blocked by local blood clotting, resulting in the death of the tissue served by that artery.
- Restenosis, the recurrence of stenosis or artery stricture after corrective surgery, is an accelerated form of atherosclerosis. Recent evidence has supported a unifying hypothesis of vascular injury in which coronary artery restenosis along with coronary vein graft and cardiac allograft atherosclerosis can be considered to represent a much-accelerated form of the same pathogenic process that results in spontaneous atherosclerosis. Restenosis is due to a complex series of fibroproliferative responses to vascular injury involving potent growth-regulatory molecules, including platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), also common to the later stages in atherosclerotic lesions, resulting in vascular smooth muscle cell proliferation, migration and neointimal accumulation.
- Restenosis occurs after coronary artery bypass surgery (CAB), endarterectomy, and heart transplantation, and particularly after heart balloon angioplasty, atherectomy, laser ablation or endovascular stenting (in each of which one-third of patients redevelop artery-blockage (restenosis) by 6 months), and is responsible for recurrence of symptoms (or death), often requiring repeat revascularization surgery. Despite over a decade of research and significant improvements in the primary success rate of the various medical and surgical treatments of atherosclerotic disease, including angioplasty, bypass grafting and endarterectomy, secondary failure due to late restenosis continues to occur in 30-50% of patients.
- The most effective way to prevent this disease is at the cellular level, as opposed to repeated revascularization surgery which can carry a significant risk of complications or death, consumes time and money, and is inconvenient to the patient.
- As used herein, the following terms in quotations shall have the indicated meanings, whether in plural or singular form:
- “Amino acid acyl group” in the amino acid acylamino group is an acyl group derived from the amino acid. The amino acids may be enumerated by α-amino acids, β-amino acids and γ-amino acids. Examples of preferred amino acids include glycine, alanine, leucine, serine, lysine, glutamic acid, asparatic acid, threonine, valine, isoleucine, ornithine, glutamine, asparagines, tyrosine, phenylalanine, cysteine, methionine, arginine, β-alanine, tryptophan, proline, histidine, etc. The preferred amino acid is serine and the preferred amino acid acyl group is a serinamide.
- “Amine” refers to a free amine NH2 or a lower alkylamino.
- “Animal” refers to any warm-blooded mammal, preferably a human.
- “Alkyl” refers to a group containing from 1 to 8 carbon atoms and may be straight chained or branched. An alkyl group is an optionally substituted straight, branched or cyclic saturated hydrocarbon group. When substituted, alkyl groups may be substituted with up to four substituent groups, R as defined, at any available point of attachment. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with “branched alkyl group”. Exemplary unsubstituted such groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like. Exemplary substituents may include but are not limited to one or more of the following groups: halo (such as F, Cl, Br, I), haloalkyl (such as CCl3 or CF3), alkoxy, alkylthio, hydroxy, carboxy (—COOH), alkyloxycarbonyl (—C(O)R), alkylcarbonyloxy (—OCOR), amino (—NH2), carbamoyl (—NHCOOR— or —OCONHR—), urea (—NHCONHR—) or thiol (—SH). Alkyl groups as defined may also comprise one or more carbon to carbon double bonds or one or more carbon to carbon triple bonds.
- “Aryl” refers to groups with aromaticity, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, as well as multicyclic systems with at least one aromatic ring. Examples of aryl groups include benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, etc. The preferred aryl group of the present invention is a benzene ring.
- “Aroyl” refers to the —(C═O)-aryl groups, wherein aryl is defined as hereinabove. The aryl group is bonded to the core compound through a carbonyl bridge.
- “Cycloalkyl” is a species of alkyl containing from 3 to 15 carbon atoms, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings. Exemplary unsubstituted such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, etc. Exemplary substituents include one or more of the following groups: halogen, alkyl, alkoxy, alkyl hydroxy, amino, nitro, cyano, thiol and/or alkylthio.
- “Halogen” or “Halo” refers to chlorine, bromine, fluorine or iodine.
- “Lower alkoxy” refers to —O-alkyl groups, wherein alkyl is as defined hereinabove. The alkoxy group is bonded to the core compound through the oxygen bridge. The alkoxy group may be straight chained or branched; although the straight-chain is preferred. Examples include methoxy, ethyloxy, propoxy, butyloxy, t-butyloxy, i-propoxy, and the like. Preferred alkoxy groups contain 1-4 carbon atoms, especially preferred alkoxy groups contain 1-3 carbon atoms. The most preferred alkoxy group is methoxy.
- “Lower alkylamino” refers to a group wherein one or two alkyl groups is bonded to an amino nitrogen, i.e., NH(alkyl). The nitrogen is the bridge connecting the alkyl group the core compound. Examples include NHMe, NHEt, NHPr, and the like.
- “Prodrug” refers to a precursor form of the drug which is metabolically converted in vivo to produce the active drug. Preferred prodrugs of the present invention include the phosphate, phosphoramidate, or amino acid acyl groups as defined herein. The phosphate ester salt moiety may also include (—OP(O)(O-alkyl)2 or (—OP(O)(O—NH4 +)2).
- “Phenolic moiety” means herein a hydroxy group when it refers to an R group on an aryl ring.
- “Phosphate”, “Phosphate moiety”, or “Phosphate prodrug salt” refers to phosphate ester salt moiety (—OP(O)(O−M+)2), a phosphate triester moiety (—OP(O)(OR)2) or a phosphate diester moiety (—OP(O)(OR)(O−M+), where M is a salt and R is chosen to be any appropriate alkyl or branched alkyl substituent (the two R groups may be the same alkyl group or may be mixed), or benzyl, or aryl groups. The salt M is advantageously Na, K and Li, but the invention is not limited in this respect.
- “Phosphoramidate” refers to a phosphoamidate ester salt moiety (—NP(O)(O−M+)2), a phosphoramidate diester moiety (—NP(O)(OR)2), or a phosphamidate disalt moiety (—NP(O)(OR)(O−M+), where M is a salt and R is chosen to be any appropriate alkyl or branched alkyl substituent (the two R groups may be the same alkyl group or may be mixed), or benzyl, or aryl groups. The salt M is advantageously Na, K and Li, but the invention is not limited in this respect.
- “Salt” is a pharmaceutically acceptable salt and can include acid addition salts such as the hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, and tartrates; alkali metal cations such as Na, K, Li, alkali earth metal salts such as Mg or Ca or organic amine salts such as those disclosed in PCT International Application Nos. WO02/22626 or WO00/48606.
- “Tubulin Binding Agent” shall refer to a ligand of tubulin or a compound capable of binding to either αβ-tubulin heterodimers or microtubules and interfering with the polymerization or depolymerization of microtubules.
- “Tumors”, “Cancers”, or “Neoplastic Disease” shall be used interchangeably and include (but are not limited to) the following:
- 1) carcinomas, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
- 2) hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma;
- 3) hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia;
- 4) tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma;
- 5) tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and
- 6) other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer, anaplastic thyroid cancer and Kaposi's sarcoma.
- “Vascular toxicity” refers to the selective destruction, damage, or occlusion, whether reversible or irreversible, partial or complete, of proliferating vasculature.
- “Malignant proliferating vasculature” refers to the endothelium, artery, blood vessel, or neovasculature formed by a malignant disease state, such as a tumor.
- “Nonmalignant proliferating vasculature” refers to the endothelium, artery, blood vessel, or neovasculature formed by undesirable or pathological angiogenesis and that is associated with disease states other than a malignant disease state, including without limitation ocular diseases such wet or age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, diabetic molecular edema, uveitis, and corneal neovascularization, or other nonocular disease states such as psoriasis, rheumatoid arthritis, atheroma, restenosis, Kaposi's sarcoma, haemangioma, and in general, inflammatory diseases characterized by vascular proliferation.
- “Antiproliferative” or “antimitotic” refer to the ability of the compounds of the present invention to directly inhibit the proliferation of tumor cells and impart direct cytotoxicity towards tumor cells.
- “Treating” (or “treat”) as used herein includes its generally accepted meaning which encompasses prohibiting, preventing, restraining, and slowing, stopping, or reversing progression, severity, of a resultant symptom. As such, the methods of this invention encompass both therapeutic and prophylactic administration.
- “Effective amount” refers to the amount or dose of the compound, upon single or multiple dose administration to the patient, which provides the desired effect in the patient under diagnosis or treatment.
- An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount or dose of compound administered, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
- A typical daily dose will contain from about 0.1 mg/kg to about 1000 mg/kg of the active compound of this invention. Preferably, daily doses will be about 10 mg/kg to about 100 mg/kg, and most preferably about 10 mg.
- In effecting treatment of a patient afflicted with a condition, disease or disorder described herein, a compound of the present invention can be administered systemically in any form or mode which makes the compound bioavailable in effective amounts. Systemic administration may be accomplished by administration of a compound of the present invention into the bloodstream at a site which is separated by a measurable distance from the diseased or affected organ or tissue. For example, compounds of the present invention can be administered orally, parenterally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, buccally, and the like. Oral or intravenous administration is generally preferred for treating neoplastic disease or cancer. Alternatively, the compound may be administered non-systemically by local administration of the compound of the present invention directly at the diseased or affected organ or tissue. Treatment of ocular diseases characterized by the presence of non-malignant proliferative vasculature or neovascularization, can be achieved using non-systemic administration methods such as intravitreal injection, sub-Tenon's injection, ophthalmic drops, iontophoresis, topical formulation and implants and/or inserts. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the disease state to be treated, the stage of the disease, and other relevant circumstances.
- It will be understood by the skilled reader that all of the compounds used in the present invention are capable of forming salts, and that the salt forms of pharmaceuticals are commonly used, often because they are more readily crystallized and purified than are the free bases. In all cases, the use of the pharmaceuticals described above as salts is contemplated in the description herein, and often is preferred, and the pharmaceutically acceptable salts of all of the compounds are includes in the names of them.
- According to another aspect, the present invention provides a pharmaceutical composition, which comprises a compound of the present invention or a pharmaceutically acceptable salt thereof as defined hereinabove and a pharmaceutically acceptable diluent or carrier.
- The pharmaceutical compositions are prepared by known procedures using well-known and readily available ingredients. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, and may be in the form of a capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active ingredient. The compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments containing, for example, up to 10% by weight of active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum, acacia, calcium phosphate, alginates, tragcanth, gelatin, calcium silicate, micro-crystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, methyl cellulose, methyl and propyl hydroxybenzoates, talc, magnesium stearate, and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents, or flavoring agents. Compositions of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well know in the art.
- The compositions are preferably formulated in a unite dosage form, each dosage containing from about 1 mg to about 500 mg, more preferably about 5 mg to about 300 mg (for example 25 mg) of the active ingredient. The term “unit dosage form” refers to a physically discrete unit suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier, diluent, or excipient. The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way.
- The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, transdermal (e.g., patch), intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation.
- For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose of calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form, of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
- For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.
- The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in a powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension form a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.
- Tablets or capsules of the compounds may be administered singly or two or more at a time as appropriate. It is also possible to administer the compounds in sustained release formulations.
- The physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
- The compounds of the present invention can be administered by inhalation or in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. An alternative means of transdermal administration is by use of a skin patch. For example, they can be incorporated into a cream consisting of an aqueous emulsion of polyethylene glycols or liquid paraffin. They can also be incorporated, at a concentration of between 1 and 10% by weight, into an ointment consisting of a white wax or white soft paraffin base together with such stabilizers an preservatives as may be required.
- “Administering” means any of the standard methods of administering a compound to a subject, known to those skilled in the art. Examples include, but are not limited to intravenous, intramuscular or intraperitoneal administration.
- The clonogenic toxicity may be increased by imbalancing Ca2+ cytosolic levels or nucleotide pools or in combination thereof.
- For the purposes of this invention “pharmaceutically acceptable carriers” means any of the standard pharmaceutical carriers. Examples of suitable carriers are well known in the art and may-include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solutions phosphate buffered saline containing POLYSORB 80, water, emulsions such as oilwater emulsion, and various type of wetting agents. Other carrier may also include sterile solutions, tablets, coated tablets, and capsules.
- Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay gelatin, stearic acid or salts thereof, magnesium or calcium stearate, talc, vegetable fats or oils, gums glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. Compositions comprising such carriers are formulated by well known convention methods.
- Methods of determining an “effective amount” are well known to those skilled in the art and depend upon factors including, but not limited to: the size of the patient and the carrier used.
- The invention is further defined by reference to the following examples and preparations which describe the manner and process of making and using the invention and are illustrative rather than limiting. It will be apparent to those skilled in the art that many modifications, both to the materials and methods, may be practiced without departing from the purpose and interest of the invention.
- The following reactions are illustrated in
FIG. 1 : - To a 1-L round-bottom flask was added Isovanillin (80 g, 526 mmol) and DMAP (1 g) under inert atmosphere. Dry dichloromethane (˜450 mL) was added, followed by triethylamine (81 mL, 580 mol), at which point the solid entirely dissolved. The mixture was cooled to 0° C. and tert-butyldimethylsilyl (“TBS”) chloride (“TBSCI”, 89 g, 590 mmol) was added in one portion. The mixture began almost immediately to precipitate solid. The mixture was allowed to stir for 1.5 h at 0° C., at which point TLC (30% EtOAc/hexanes) showed an almost complete absence of isovanillin. The mixture was allowed to stir overnight, then the precipitate was filtered off through Celite. The filtrate was washed with water (200 mL) followed by saturated NaCl solution (200 mL) and dried over MgSO4. This was filtered into a tared 1-L flask and concentrated by distillation on a rotary evaporator, followed by aspirator vacuum to approximately constant weight, yielding a deep red-brown liquid (149.4 g; theoretical=140 g). This material was taken into the next reaction without further characterization.
- The entire crude product from the preceding reaction (-526 mol) was-transferred as a solution in dry ether (200 mL) to a 2-L round bottom flask equipped with a very large magnetic stirring bar. An additional 500 mL of dry ether were added and the mixture was cooled to 0° C. Then methyllithium (500 mL of a 1.4 M solution, 700 mmol) was added over ˜40 minutes by cannula, and the mixture was allowed to stir overnight. The deep red mixture was re-cooled to 0° C. and treated with water (200 mL) very cautiously at first. The mixture became a heterogeneous yellow. In a separatory funnel, the aqueous phase was separated and the organic phase was washed once with saturated NaCl solution and dried over MgSO4. After filtration and concentration by distillation on a rotary evaporator followed by aspirator vacuum, a deep red liquid was obtained (136.8 g), and was found to be free of starting material by TLC. This material was taken into the next reaction without further characterization.
- The entire amount of the crude alcohol from the preceding reaction was transferred to a 3-L round bottom flask as a solution in ˜1.5 L of dry dichloromethane. Celite (62 g, oven dried), K2CO3 (16 g) and a very large magnetic stirring bar were added. PCC (115 g) was then added in portions over a 2-hr period, during which time the heterogeneous yellow mixture became dark brown. At the end of the addition, large amounts of the starting alcohol were still present by TLC (25% EtOAc/hexanes) so the mixture was allowed to stir overnight. At this point, the starting alcohol was absent (or nearly so) by TLC, and the mixture was filtered through a 3-cm pad of silica gel, rinsing well with dichloromethane. The mud-brown solution was concentrated by distillation on a rotary evaporator followed by aspirator vacuum to yield an opaque brown liquid. This was purified in 30 mL portions by Kugelrohr distillation (˜0.5 Torr, 140° C.) to yield 104.4 g of a brown liquid which crystallized on brief standing. This was dissolved in hot hexanes (104 mL) and filtered hot through Celite to yield a clear yellow solution. This was seeded and left in a refrigerator (˜5° C.) overnight. The crystalline product was filtered cold, washed quickly with a small amount of cold hexanes and dried under pump vacuum to give 84.8 g (303 mol, 58% yield from isovanillin) recrystallized light yellow solid, pure by 1H and 13C NMR. A second crop of crystals (6.3 g) were obtained by dissolving the concentrated filtrate in hot hexanes (20 mL) followed by seeding and standing overnight.
- 3. 1H NMR (CDCl3): 0.15 (s, 6H); 0.98 (s, 9H); 2.52 (s, 3H); 3.85 (s, 3H); 6.85 (d, 1H, J=8.4); 7.45 (s, 1H); 7.56 (dd, 1H, J =8.4, 2.2).
- 13C NMR (CDCl3): −4.8, 18.4, 25.6, 26.3, 55.4, 110.7, 120.2, 123.5, 130.5, 144.7, 155.3, 196.8.
- An important part of the present invention is a new efficient method of converting 3-TBSO-4-methoxyacetophenone (3) to α-halo-3-TBSO-4-methoxyacetophenone (5) by treatment of the trimethylsilyl enol ether (4) [1-(3-TBSO-4-methoxyphenyl)-1-trimethylsiloxy(TMSO)-ethylene] with elemental halogen. Bromine is the preferred halogen. It is understood that chlorine and iodine may be utilized in place of bromine should iodo or chloro analogs be desired.
- A fundamental intermediate in the synthesis of the compounds of the present invention is a substituted tetralone structure (see
FIG. 8 ). - a. Synthesis of Mono-Hydroxy Substituted Tetralone
- A procedure for the synthesis of mono-hydroxy substituted tetralone from tetrahydronaphthalene is illustrated with an exemplary synthetic route in
FIG. 2 . A mixture of 6-methoxy-1,2,3,4-tetrahydronaphthalene (6) and TMEDA was treated with sec-butyllithium at room temperature followed by addition of trimethyl borate. The resultant mixture was subsequently treated with acetic acid and 35% hydrogen peroxide to form thehydroxytetrahydronaphthalenes - The 5-
hydroxy isomer 7 was converted to 5-acetoxy-6-methoxy-1,2,3,4-tetrahydronaphthalene (9) in 95% yield. Reaction of the 9 with DDQ in dioxane-water led to the formation oftetralone 10 as a single isomer in 96 % yield. The correct position of the keto group was confirmed by single-crystal X-ray crystallography. The acetate was removed by treatingtetralone 10 with sodium bicarbonate in methanol to form 5-hydroxy-6-methoxy-1-tetralone (11). - 5-Hydroxy-6-methoxy-1-tetralone (11): 1H-NMR (300 MHz, CDCl3) δ 2.11 (m, 2H), 2.60 (t, 2H, J=6.2 Hz), 2.93 (t, 2H, J=6.1 Hz), 3.95 (s, 3H), 5.75 (bs, 1H), 6.83 (d, 1H, J=8.6 Hz), 7.68 (d, 1H, J=8.6 Hz).
- b. Synthesis of Dihydroxy-Substituted Tetralones
- In order to synthesize dihydroxy-substituted dihydronaphthalenes and their corresponding prodrugs, the invention provides the synthesis di-hydroxytetralones as intermediates. The synthesis of an exemplary dihydroxy tetralone is provided in
FIG. 3 . 5,7-dihydroxy-6-methoxy-1-tetralone (19) is synthesized by protection of the 7-hydroxy group in thetetrahydronaphthalene 17 as its corresponding TBS ether (13) proceeded in high yield. In regard to regioselective introduction of the hydroxy group, we anticipated that due to different ortho-directing effects of methoxy and -OTBS groups, it should prove possible to obtain one of the isomers in much higher amount over the other. Accordingly, whentetrahydronaphthalene 13 was treated sequentially with sec-butyllithium-TMEDA, trimethylborate, acetic acid, and 35% hydrogen peroxide, and 5-hydroxy-6-methoxy-7-(tert-butyldimethylsiloxy)-1,2,3,4-tetrahydronaphthalene (14) was obtained as a single product. The TBS protecting group was removed by treatingtetrahydronaphthalene 14 with 1M TBAF in THF and the two hydroxy groups of theresultant tetrahydronaphthalene 15 were converted to the corresponding acetates to give 5,7-diacetoxy-6-methoxy-1,2,3,4-tetrahydronaphthalene (16). Unfortunately, all of our efforts to convert thetetrahydronaphthalene 16 to the corresponding tetralone failed using DDQ under various conditions. In order to overcome the problem of oxidation, we considered different oxidizing agents. After various trials, chromium (VI) oxide in acetic acid-water was found to be the reagent of choice. Thus,tetrahydronaphthalene 16 was converted to 5,7-diacetoxy-6-methoxy-1-tetralone (17) in 54% yield. Approximately 5% ofisomeric tetralone 18 was also formed. Again in this case, the para-directing effect of the methoxy group led to the formation of thetetralone 17 predominantly. The acetates intetralone 17 were removed by treatment with potassium carbonate in methanol to produce 5,7-dihydroxy-6-methoxy-1-tetralone (19). - 5,7-Diacetoxy-6-methoxy-1-tetralone (19): 1H-NMR (300 MHz, CDCl3) δ 2.08-2.14 (m, 2H), 2.32 (s, 3H), 2.36 (s, 3H), 2.61 (t, 2H, J=6.6 Hz), 2.74 (t, 2H, J=6.0 Hz), 7.69 (s, 1H).
- c. Synthesis of Amino-Functionalized Tetralones
- A procedure for the synthesis of mono-amino substituted tetralone from tetrahydronaphthalene is illustrated with an exemplary synthetic route in
FIG. 4 . To an ice-cold, stirred solution of 6-methoxy-1-tetralone (20, 17.6 g, 0.10 mol) in acetone (30 mL) was added dropwise a mixture of sulfuric acid (18 mL, 96.0%) and nitric acid (15 mL, 68.0-70.0%). After the addition was complete, the reaction was stirred at 0° C. for 6 hours, and TLC was employed to monitor the reaction progress. The reaction mixture was poured into ice-water, and the mixture was partitioned between CH2Cl2 (3×200 mL) and water (200 mL). The organic layer was washed by saturated NaHCO3 solution and water (200 mL each), dried over anhydrous sodium sulfate, and, after filtration, the organic layer was concentrated in vacuo to provide a yellow oil. 6-Methoxy-5-nitro-1-tetralone (21, 7.74 g, 0.035 mol) and 6-methoxy-7-nitro-1-tetralone (22, 6.63 g, 0.030 mol) were obtained after purification by column chromatography: - 6-Methoxy-5-nitro-1-tetralone (21): 1H-NMR (CDCl3, 300 MHz) δ 2.15 (m, 2H), 2.65 (t, J=6.2 Hz, 2H), 2.87 (t, J=6.0 Hz, 2H), 7.02 (d, J=8.7 Hz, 1H), 8.19 (d, J=8.9 Hz, 1H).
- 6-Methoxy-7-nitro-1-tetralone (22): 1H-NMR (CDCl3, 300MHz) δ 2.15 (m, 2H), 2.67 (t, J=6.2 Hz, 2H), 3.01 (t, J=6.1 Hz, 2H), 6.90 (s, 1H), 8.52 (s, 1H).
- To a solution of acetic acid (20 mL) in H2O (100 mL), 7-nitro-6-methoxy-1-tetralone (21) (2.21 g, 10.0 mol) was added. The solution was heated to reflux for 1 hour, and then cooled down to RT. NaHCO3 (60 mL, saturated solution) was added, and the mixture was partitioned between CH2Cl2 and water. The organic layer was dried over anhydrous sodium sulfate. After filtration, the organic layer was concentrated in vacuo to provide (23) as a red oil.
- 7-Amino-6-methoxy-1-tetralone (23): (1.74 g, 9.1 mol, 91%) 1H-NMR (CDCl3, 300 MHz) 2.07 (m, 2H), 2.57 (t, J=6.5 Hz, 2H), 2.86 (t, J=6.0 Hz, 2H), 3.73 (b, 2H), 2.91 (s, 3H), 6.59 (s, 1H), 7.36 (s, 1H).
- Hydroxy-functionalized tetralones were also obtained from amino-functionalized counterpart. For example, 23 (0.96 g, 5.0 mol) was dissolved in a mixture of sulfuric acid (96%, 2.1 mL) and H2O (3.9 mL). The solution was cooled to 0 C, and ice (5.0 g) was added resulting in the crystallization of a solid. A solution of NaNO2 (0.48 g, 7 mol) in H2O (5 mL) was added dropwise at 0° C., After the solution had been stirred for an additional 10 min, a few crystals of urea were added to decompose any excess sodium nitrite. To the cold solution of benzenediazonium bisulfate was added a solution of cupric nitrate trihydrate (19.0 g, 78.6 mol) in H2O (150 mL) at 0° C. With vigorous stirring, cuprous oxide (0.72 g, 5.0 mol) was added to the solution. The solution was stirred for 10 more min, and TLC was employed to monitor the reaction. The mixture was partitioned between ethyl ether and water. The organic layer was dried over anhydrous sodium sulfate, and after filtration, the organic layer was concentrated in vacuo to provide (12) as a yellow oil.
- 7-Hydroxy-6-methoxy-1-tetralone (12): (0.22 g, 1.15 mol, 23%) 1H-NMR (CDCl3, 300 MHz) 2.09 (m, 2H), 2.59 (t, J=6.5 Hz, 2H), 2.88 (t, J=6.0 Hz, 2H), 3.95 (s, 1H), 6.66 (s, 1H), 7.56 (s, 1H). C-NMR (CDCl3, 75 MHz) 23.6, 29.5, 38.6, 56.0, 109.6, 112.2, 126.5, 138.4, 144.4, 151.0, 197.2.
- Our interest in preparing the following aryl-substituted dihydronaphthalene ligands was based on our molecular recognition studies which suggest an optimal aryl-aryl distance (centroid to centroid) for enhanced tubulin binding. Exemplary aryl-substituted dihydronaphthalene ligands are depicted in
FIG. 5A . - Each aryl-substituted compound was synthesized according the generalized synthetic scheme illustrated in
FIG. 8 . - a. Synthesis of Aryl-substituted Tetrahydronaphthalen-1-ol
- To a stirred solution of n-butyllithium (3.7 mL, 1.6 M in hexane solution, 6.0 mol) in dry ether (40 mL), a solution of 3,4,5-trimethoxyphenylbromide (0.74 g, 3.0 mol) in ether (20 mL) was added under dry nitrogen at −78° C. The solution was stirred for 1 h in order to form 3,4,5-trimethoxyphenyllithum (“TPL”). Substituted tetralone reagent (3.0 mol) was added at −20° C., and the stirring was continued for 2 h (−20° C.—RT). The mixture was partitioned between CH2Cl2 and water, the organic layer was dried over anhydrous sodium sulfate, and, after filtration, the organic layer was concentrated in vacuo to provide a tetrahydronaphthalen-1-ol as a yellow oil. Each compound was purified by column chromatography.
- Oxi-com 146 (24) (61% yield) 1H-NMR (CDCl3,300MHz) δ 1.82 (m, 1H), 1.96 (m, 1H), 2.10 (t, J=5.7 Hz, 2H), 2.82 (t, J=5.9 Hz, 2H), 3.68 (s, 3H), 3.78 (s, 3H), 6.55 (s, 2H), 6.22 (d, J=2.6 Hz, 1H), 6.80 (dd, J=2.7, 8.4 Hz, 1H), 7.08 (d, J=8.4 Hz, 1H). 13C-NMR (CDCl3, 75 MHz) δ 14.1, 19.8, 28.9, 41.3, 55.3, 56.1, 60.8, 75.7, 103.8, 113.0, 114.3, 129.7, 129.9, 136.5, 142.6, 144.4, 152.5, 157.9. HRMS (EI) M+, calcd for C20H24O5 344.1624, found 344.1622.
- Oxi-com 150 (25) (41% yield) 1H-NMR (CDCl3, 300 MHz) δ 1.84 (m, 1H), 2.00 (m, 1H), 2.12 (m, 2H), 2.22 (s, 1H), 2.67 (m, 1H), 2.94 (m, 1H), 3.78 (s, 6H), 3.85 (s, 3H), 3.87 (s, 3H), 6.55 (s, 2H), 6.70 (d, J=8.0 Hz, 1H), 6.77 (d, J=8.1 Hz, 1H), 7.13 (t, J=7.9 Hz, 1H). 13C-NMR (CDCl3, 75MHz) δ 19.2, 23.6, 41.0, 55.7, 56.4, 61.1, 75.8, 104.1, 108.8, 120.9, 126.9, 127.1, 136.7, 143.0, 145.0, 152.8, 157.0. HRMS (EI) M+, calcd for C20H24O5 344.1624, found 344.1622.
- Oxi-com 156 (26) (58% yield) 1H-NMR (CDCl3, 300 MHz) 6 1.82 (m, 1H), 2.00 (m, 4H), 2.88 (t, J=6.2, 2H), 3.79 (s, 6H), 3.80 (s, 3H), 3.85 (s, 3H), 6.57 (s, 2H), 6.69 (m, 2H), 6.99 (d, J=7.5 Hz, 1H). 13C-NMR (CDCl3, 75MHz) δ 19.7, 30.2, 41.4, 55.2, 56.1, 60.8, 75.2, 103.7, 112.8, 112.9, 130.2, 134.1, 136.4, 139.1, 144.9, 152.5, 158.7. HRMS (EI) M+, calcd for C20H2405 344.1624, found 344.1626.
- b. Synthesis of Aryl-Substituted Dihydronaphthalenes.
- To a solution of acetic acid (10 mL) in H2O (60 mL), compounds 24, 25, 26, (1 mol) were added respectively. The solution was heated to reflux for 1 hour, and then cooled down to RT. NaHCO3 (20 mL, saturated solution) was added, and the mixture was partitioned between CH2Cl2 and water. The organic layer was dried over anhydrous sodium sulfate, after filtration, the organic layer was concentrated in vacuo to provide the following compounds as a yellow oil. Each compound was purified by column chromatography.
- Oxi-com 148 (27) (92% yield) 1H-NMR (CDCl3, 300MHz) δ 2.83 (m, 2H), 2.79 (t, J=7.7 Hz, 2H), 3.71 (s, 3H), 3.85 (s, 6H), 3.89 (s, 3H), 6.11 (t, J=4.6 Hz, 1H), 6.57 (s, 2H), 6.65 (d, J=2.6 Hz, 1H), 6.73 (dd, J=2.6, 8.2 Hz, 1H), 7.13 (d, J=8.2 Hz, 1H). 13C-NMR (CDCl3, 75 MHz) δ 24.1, 27.6, 55.7, 56.4, 61.3, 106.0, 112.0, 112.3, 128.4, 128.5, 129.2, 136.3, 136.7, 137.3, 140.1, 153.3, 158.4. HRMS (EI) M+, calcd for C20H22O4 326.1518, found 326.1507. Anal. Calcd for C20H22O4: C, 73.60; H, 6.79. Found: C, 73.77; H, 6.93.
- Oxi-com 153 (28) (90% yield) 1H-NMR (CDCl3, 300 MHz) 6 2.39 (m, 2H), 2.86 (t, J=8.3 Hz, 2H), 3.84 (s, 6H), 3.87 (s, 3H), 3.89 (s, 3H), 6.10 (t, J=4.6 Hz, 1H), 6.55 (s, 2H), 6.71 (d, J=7.7 Hz, 1H), 6.82 (d, J=8.2 Hz, 1H), 7.11 (t, J=8.1 Hz, 1H). 13C-NMR (CDCl3, 75 MHz) δ 19.8, 22.8, 55.6, 56.1, 60.9, 105.7, 109.7, 118.5, 124.5, 126.2, 127.7, 136.0, 136.8, 136.9, 139.7, 152.8, 156.0. HRMS (EI) M+, calcd for C20H22O4 326.1518, found 326.1518. Anal. Calcd for C20H22O4: C, 73.60; H, 6.79. Found: C, 73.77; H, 6.84.
- Oxi-com 141 (29) (90% yield) 1H-NMR (CDCl3, 300 MHz) δ 2.83 (m, 2H), 2.83 (t, J=7.6 Hz, 2H), 3.82 (s, 3H), 3.85 (s, 6H), 3.89 (s, 3H), 5.95 (t, J=4.5Hz, 1H), 6.56 (s, 2H), 6.66 (dd, J=2.6, 8.4 Hz, 1H), 6.73 (d, J=2.6 Hz, 1H), 7.00 (d, J=8.4 Hz, 1H). 13C-NMR (CDCl3, 75 MHz) δ 23.8, 29.2, 55.7, 56.5, 61.4, 106.1, 111.2, 114.2, 125.2, 127.1, 128.5, 137.1, 137.4, 139.0, 139.9, 153.4, 159.0. HRMS (EI) M+, calcd for C20H22O4 326.1518, found 326.1515.
- a) Synthesis of Amino, Aryl-Substituted Dihydronaphthalene Analogs
- Amine, Aryl-substituted dihydronaphthelene compounds and their corresponding prodrugs are contemplated as part of the invention. Exemplary compounds are depicted in
FIG. 5 . The C-5 amine dihydronaphthalene derivative, Oxi-com 142 (31), and its phosphoramidate prodrug Oxi-com 143 (32) were synthesized as illustrated inFIG. 9 . - To a stirred solution of n-butyllithium (15.0 mL, 1.6 M in hexane solution, 24.0 mol) in dry ether (160 mL), a solution of 3,4,5-trimethoxyphenylbromide (2.97 g, 12.0 mol) in ether (40 mL) was added under dry nitrogen at −78° C. The solution was stirred for 1 h in order to form 3,4,5-trimethoxyphenyllithum.
- 6-Methoxy-5-nitro-1-tetralone (21) (2.65 g, 12.0 mol) was added at −20 ° C. to the trimethoxyphenyllithium and stirring was continued for 2 h (−20° C.—RT). The mixture was partitioned between CH2Cl2 and water, the organic layer was dried over anhydrous sodium sulfate, and, after filtration, the organic layer was concentrated in vacuo, to afford 1-Hydroxy-6-methoxy-5-nitro-1-(3′,4′,5′-trimethoxyphenyl)tetralin (30) as a crude yellow oil. (GC-MS shows the yield is about 55%). This compound, without purification, was added to a refluxing mixture of acetic acid (10 mL) and water (80 mL), and iron (0.5 g) was added. After heating at reflux for 1 h, the mixture was partitioned between CH2Cl2 (3×100 mL) and water (100 mL). The organic layer was washed with NaHCO3 (sat.) and water (100 mL each), dried over anhydrous sodium sulfate, and, after filtration, the organic layer was concentrated in vacuo to provide a yellow oil. Purification by column chromatography afforded 5-Amino-6-methoxy-1-(3′,4′,5′-trimethoxyphenyl)-3,4-dihydronaphthalene (31):
- Oxi-com 142 (31) (2.03 g, 5.95 mol). 1H-NMR (CDCl3, 300 MHz) δ 2.43 (m, 2H), 2.68 (t, J=7.8 Hz, 2H), 3.84 (s, 6H), 3.86 (s, 3H), 3.89 (s, 3H), 5.93 (t, J=4.7 Hz, 1H), 6.51 (d, J=8.4 Hz, 1H), 6.56 (s, 2H), 6.60 (d, J=8.4 Hz, 1H). 13C-NMR (CDCl3, 75 MHz) δ 22.0, 23,3, 56.0, 56.5, 61.3, 106.4, 107.5, 117.2, 121.6, 124.5, 128.6, 132.8, 137.4, 137.6, 140.4, 147.5, 153.2. HRMS (EI) M+, calcd for C20H23NO4 341.1627, found 341.1635. Anal. Calcd for C20H23NO4: C, 70.36; H, 6.79; N: 4.10. Found: C, 70.24; H, 6.74; N, 4.08.
- To a stirred solution of C1P(OC2H5)2 (0.157 g, 1.0 mol) in dry ethyl ether (20 mL) was added slowly a solution of 31 (0.341 g, 1 mol) in dry ethyl ether (30 mL) at −78° C. Once this addition was complete, a solution of N, N-diisopropylethylamine (0.28 g, 2.2 mol) in dry ethyl ether (2 mL) was added. The solution was stirred at −78° C. for 2 hours, followed by stirring at RT for 10 hours. The solution was filtered and concentrated in vacuo to provide a yellow oil. The yellow oil was dissolved in dry CH2Cl2 (10 mL), then cooled to −40° C. A solution of MCPBA (0.28 g) in dry CH2Cl2 (10 mL) was added. After stirring at RT for 1 h, the organic layer was washed with saturated Na2SO4 solution and water (10 mL each), dried over anhydrous sodium sulfate, and, after filtration, the organic layer was concentrated in vacuo to provide a yellow oil. Purification by column chromatography afforded 6-methoxy-1-(3′,4′,5′-trimethoxyphenyl)-5-diethylphosphoramidate-3,4-dihydronaphthalene (32):
- Oxi-com 143 (32): (0.286 g, 0.60 mol). 1H-NMR (CDCl3, 300 MHz) δ 1.33 (t, J=7.0 Hz, 6H), 2.75 (t, J=8.5 Hz, 2H), 3.21 (t, J=8.6 Hz, 2H), 3.82 (s, 3H), 3.84 (s, 6H), 3.92 (s, 3H), 4.11 (m, 4H), 6.46 (s, 2H), 6.50 (d, J=8.4 Hz, 1H), 6.57 (d, J=8.6 Hz, 1H). 13C-NMR (CDC13, 75MHz) δ16.2, 16.3, 24.8, 32.4, 55.6, 56.2, 61.0, 62.9, 63.0, 107.0, 107.6, 123.7, 124.7, 129.1, 131.4, 133.4, 134.8, 152.8, 153.1. 31P-NMR (CDCl3, 300MHz) δ 6.51. HRMS (EI) M+, calcd for C24H32NPO7477.1916, found 477.1928.
- Acyl amino acid ester prodrugs of Amino, Aryl-Substituted Dihydronaphthalene Analogs were also synthesized. The L-serinamide prodrug derivative of 31 was obtained by dissolving 3,4-dihydro-5-FMOC-L-serinamide-6-methoxy-1-(3′,4′,5′-trimethoxyphenyl) naphthalene (0.0435 g, 0.0679 mmol) in CH2Cl2 (1.2 mL) and CH3OH (1.2 mL). While stirring, NaOH (0.003 g, 0.000075 mmol) was added and allowed to react at room temperature for 16 h. After completion, extraction of the organic layer was accomplished with EtOAc, water, and saturated NaCl (100 mL each). The organic layer was dried with anhydrous sodium sulfate. Purification by preparative TLC and flash column chromatography (silica gel, 90:10 methylene chloride:methanol) afforded the desired serinamide product (33)
- Oxi-com 229 (33): (0.010 g, 0.024 mmol, 36%) 1H-NMR (CDCl3, 300 MHz) δ 2.30 (m, 2H) 2.70 (t, J=7.70 Hz, 2 H), 3.77 (s, 3 H), 3.82 (s, 6H), 3.89 (s, 3 H), 4.00 (m, 3H), 5.98 (t, J=4.45 Hz, 1H), 6.57 (s, 2H), 6.67 (d, J=8.55 Hz, 1H), 6.98 (d, J=8.55 Hz, 1H), 13C-NMR (CDCl3, 300 MHz) δ 23.0, 24.0, 55.8, 56.1, 60.9, 105.8, 107.7, 125.1, 128.8, 135.3, 136.7, 139.5, 152.8, 152.9
- b) Synthesis of Hydroxy-Dihydronaphthalene Analogs
- Dihydronaphthalene compounds functionalized with hydroxy groups are contemplated in the present invention. Exemplary compounds are depicted in
FIG. 6A . The exemplary C-7 hydroxy-dihydronaphthalene analog Oxi-com 158 (36) was synthesized based on the synthetic pathway illustrated inFIG. 10 . - To a well-stirred solution of 7-Hydroxy-6-methoxy-1-tetralone (12, 80.0 mg, 0.42 mol) in CH2Cl2, was added Et3N (47 mg, 0.46 mol), followed by DMAP (5.1 mg, 0.042 mol) and TBSCI (69 mg, 0.46 mol) at 0° C. under dry nitrogen. After 2 h (at rt), the mixture was partitioned between CH2Cl2 and water. The organic layer was dried over anhydrous sodium sulfate, and after filtration, the organic layer was concentrated in vacuo to provide (34) as a yellow oil.
- 7-TBSO-6-methoxy-1-tetralone(34): (122 mg, 0.40 mol, 95%) 1H-NMR (CDCl3, 300 MHz) 0.15 (s, 6H), 0.99 (s, 9H), 2.11 (m, 2H), 2.58 (t, J=6.1 Hz, 2H), 2.88 (t, J=6.0 Hz, 2H), 3.86 (s, 3H), 6.63 (s, 1H), 7.56 (s, 1H).
- To a stirred solution of n-butyllithium (0.5 mL, 1.6 M in hexane solution, 0.80 mol) in dry ether (20 mL), a solution of 3,4,5-trimethoxyphenylbromide (98.8 mg, 0.40 mol) in ether (10 mL) was added under dry nitrogen at −78° C. The solution was stirred for 1 h in order to form 3,4,5-trimethoxyphenyllithum. 7-[(tertButyldimethylsilyl)oxy]-6-methoxy-1-tetralone (122 mg, 0.40 mol) was added at −20° C., and stirring was continued for 2 h (−20° C.—rt). The mixture was partitioned between CH2Cl2 and water, and the organic layer was dried over anhydrous sodium sulfate. After filtration, the organic layer was concentrated in vacuo to provide (35) as a yellow oil.
- 7-TBSO-1-hydroxy-6-methoxy-1-(3′,4′,5′-trimethoxyphenyl)-tetralone (35): (137 mg, 0.29 mol, 73%) 1H-NMR (CDCl3, 300MHz) 0.04 (s, 6H), 0.89 (s, 9H), 1.80 (b, 2H), 2.11 (m, 4H), 2.81 (t, J=6.5, 2H), 3.79 (s, 6H), 3.81 (s, 3H), 3.84 (s, 3H), 6.49 (s, 1H), 6.56 (s, 2H), 6.59 (s, 1H). 13C-NMR (CDCl3, 75MHz) −4.3, 18.8, 20.2, 26.1, 29.9, 41.5, 55.8, 56.5, 61.2, 75.6, 104.2, 111.9, 121.2, 131.4, 134.2, 136.8, 143.8, 145.3, 150.9, 152.9.
- To a solution of acetic acid (10 mL) in H2O (60 mL), was added 7-TBSO-1-hydroxy-6-methoxy-1-(3′,4′,5′-trimethoxyphenyl)-tetralone (137 mg, 0.29 mol). The solution was heated to reflux for 8 hour, and then cooled down to RT. NaHCO3 (20 mL, saturated solution) was added, and the mixture was partitioned between CH2Cl2 and water. The organic layer was dried over anhydrous sodium sulfate, and after filtration, the organic layer was concentrated in vacuo to provide 36 as a yellow oil.
- Oxi-com 158 (36) (84.3 mg, 0.25 mol, 86%) 1H-NMR (CDCl3, 300MHz) 2.37 (m, 2H), 2.78 (t, J=7.7 Hz, 2H), 3.84 (s, 6H), 3.88 (s, 3H), 3.91 (s, 3H), 5.41 (s, 1H), 5.98 (t, J=4.6 Hz, 1H), 6.54 (s, 2H), 6.68 (s, 1H), 6.81 (s, 1H).
- Similar dihydronaphthalenes functionalized in an analogous fashion at any other carbon position can readily be prepared. An exemplary detailed synthesis for the preparation of Oxi-com 196 is provided in
FIG. 11 . - Oxi-com 196 (37):— 1H-NMR (300 MHz): δ 2.34-2.41 (2H, m), 2.88 (2H, t, J=7.6 Hz), 3.84 (6H, s), 3.88 (6H, s), 5.72 (1H, s), 5.97 (1H, t, J=4.6 Hz), 6.55 (2H), 6.59 (1H, d, J=8.4 Hz), 6.63 (1H, d, J=8.4 Hz). 3C-NMR (75 MHz): δ 20.04, 22.62, 55.7, 55.87, 60.72, 105.63, 107.05, 117.21, 122.13, 125.18, 128.73, 136.,72, 136.75, 139.32, 141.8, 145.68, 152.67.
- Oxi-com 238 (38): 1H NMR (CDCl3, 360 MHz): δ 7.08 (d, J=8.9 Hz, 1H), δ 6.53 (m, 3H), δ 6.26 (d, J=8.3 Hz, 1H), δ 5.86 (t, J=4.6 Hz, 1H), δ 5.67 (s, 1H), δ 3.84 (s, 6H), δ 3.68 (s, 3H), 6 2.91 (m, 2H), 2.4 (m, 2H).
- Oxi-com 240 (39) 1H NMR (CDCl3, 360 MHz): δ 6.81 (m, 3H), δ 6.55 (d, J=8.6 Hz, 1H), δ 6.27 (d, J=7.9 Hz, 1H), δ 5.9 (t, J=4.6 Hz, 1H), δ 5.67 (s, 1H), δ 3.85 (s, 3H), δ 3.77 (s, 3H), δ 3.65 (s, 3H), δ 2.92 (m, 2H), 6 2.41 (m, 2H).
- Oxi-com 242 (40) 1H NMR (CDCl3, 300 MHz): δ 6.88 (m, 3H), δ 6.62 (d, J=8.4 Hz, 1H), δ 6.57 (d, J=8.4 Hz, 1H), δ 5.95 (t, J=4.7 Hz, 1H), δ 5.72 (s, 1H), δ 3.92 (s, 3H), δ 3.88 (s, 3H), δ 3.86 (s, 3H), δ 2.88 (t, J=7.7 Hz, 2H), δ 2.4 (m, 2H).
- d) Synthesis of Dihydronaphthalene Phosphate Prodrugs
- Phosphate Prodrugs in the form of phosphate salts and esters of hydroxyl functionalized dihydronaphthalene derivatives (and related phenolic analogs) are envisioned, for example phosphate ester disodium salts of C-5 (Oxi-
com 197, 43) and C-7 Dihydronaphthalene (42) as illustrated inFIG. 6B . We have developed a synthetic route which will readily yield the C-5 disodium phosphate salt of dihydronaphthalene by phosphorylation of 37 illustrated inFIG. 11 . - The phenol Oxi-com 196 (37) was converted to its disodium phosphate prodrug salt using by sequential treatment of CCl4, iPr2Net, DMAP, and dibenzylphosphite in acetonitrole to produce the dibenzyl phosphate derivative (46) in 86% yield. The dibenzyl phosphate derivative was then stirred with NaI and TMS1 in acetonitrile at RT for 30 min to debenzylate the compound. After removal of acetonitrile and drying, the residue was stirred overnight with NaOMe in methanol to form a salt. Crystallization in acetone-water produced the prodrug Oxi-
com 197 as a white powder. - Oxi-com 197 (43): 1H-NMR (300 MHz) δ 2.31-2.35 (2H, m), 2.94 (2H, t, J=7.7 Hz), 3.80 (6H, s), 3.82 (6H, s), 6.07 (1H, t, J=4.3 Hz), 6.72-6.74 (4H, overlapping singlet and two doublets). 13C-NMR (90.55 MHz) δ 24.64, 25.32, 58.35, 58.81, 63.83, 109.08, 111.84, 123.63, 129.55, 131.00, 134.39, 138.61, 140.63, 141.40, 142.85, 154.49, 155.06. 31P-NMR (121.48 MHz) δ 4.33
- Related phosphate prodrug derivatives of the 1-trimethoxyphenyl-dihydronaphthalene system (
FIG. 3B ) were synthesized in a similar fashion. - Oxi-com 239 (44) 1H NMR (D2O, 360 MHz): δ 7.22(d, J=8.1 Hz, 1H), δ 6.72 (m, 3H), δ 6.46 (d, J=8.7 Hz, 1H), δ 5.99 (t, J=4.6 Hz, 1H), δ 3.91 (s, 3H), δ 3.82 (s, 3H), δ 3.71 (s, 3H), δ 3.05 (m, 2H), δ 2.39 (m, 2H). 31P NMR (D2O, 360 MHz): δ 1.9 (s, 1P)
- Oxi-com 241 (45) 1H NMR (D2O, 360 MHz): δ 7.1 (d, J=9.0 Hz, 1H), 6 7.04 (dd, J=8.9 Hz, J=3.1 Hz, 3H), δ 6.93 (d, J=3.1 Hz, 1H), δ 6.74 (d, J=8.7, 1H), δ 6.45 (d, J=8.4 Hz, 1H), δ 6.0 (t, J=4.5 Hz, 1H), δ 3.83 (s, 3H), δ 3.81 (s, 3H), δ 3.67 (s, 3H), δ 3.07 (m, 2H), δ 2.4 (m, 2H).
- 31P NMR (D2O, 360 MHz): δ 1.98 (s, 1P)
- Oxi-com 243 (46) 1H NMR (D2O, 300 MHz): δ 7.1 (d, J=8.0 Hz, 1H), δ 7.02 (m, 2H), δ 6.79 (d, J=9.6 Hz, 1H), δ 6.76 (d, J=9.2 Hz, 1H), δ 6.08 (t, J=3.8 Hz, 1H), δ 3.9 (s, 3H), δ 3.84 (s, 3H), δ 3.81 (s, 3H), δ 3.07 (t, J=7.6 Hz, 2H), δ 2.32 (m, 2H).
- 31P NMR (D2O, 300 MHz): δ 4.32 (s, 1P)
- e) Synthesis of Hydroxy, Aroyl-Substituted Dihydronaphthalene and Naphthalene Prodrugs
- Aryol-substituted dihydronaphthalene ligands have previously described in U.S. Pat. No. 6,162,930. Hydroxyl functionalized derivatives and corresponding phosphate prodrugs of this compound are now provided (see
FIG. 7A ). A detailed synthetic route for this compound is illustrated inFIG. 12 . - Oxi-com 224 (47): 1H NMR: in D2O δ (PPM) 7.07 (s, 2H, Ph-H), 6.80 (d, 1H, J=8.4 Hz, Ar—H), 6.72 (d, 1H, J=8.5 Hz, Ar—H), 6.45 (t, 1H, J=4.4 vinylic-H), 3.75 (s, 3H, —OCH 3), 3.74 (s, 9H, —OCH 3), 2.82 (t, 2H, J=7.7 Hz, —CH 2), 2.37(m, 2H, —CH 2) 31P NMR: in D2O δ (PPM) —3.60 (not calibrated) Phosphate prodrugs of hydroxyl functionalized naphthalene derivatives (and related phenolic analogs) are also provided in the present invention. An exemplary compound is depicted in
FIG. 7B . This compound was synthesized as illustrated inFIG. 12 . - Oxi-com 225 (48):— 1H NMR in D2Oδ (PPM) 8.43 (d, 1H, J=8.6 Hz, Ar—H), 7.72 (d, 1H, J=9.2 Hz, Ar—H), 7.61 (t, 1H, J=6.9 Hz, Ar—H), 7.50 (d, 1H, J=6.7 Hz, Ar—H), 7.43 (d, 1H, J=9.3 Hz, Ar—H), 3.97 (s, 3H, —OCH 3), 3.87 (s, 3H, —OCH 3), 3.76 (s, 6H, —OCH 3)
- 31P NMR: in D2Oδ (PPM) −1.39 (not calibrated)
- f) Synthesis of Diphosphate Prodrugs
- It is now known that while CA4P is a potent vascular targeting and destruction agent in vivo, it is likely that CA1P (a diphosphate) may prove to be as active or even more active than CA4P in vivo. Since CA4P is enzymatically converted to CA4, which in turn interacts with tubulin to cause vascular disruption, it is reasonable to expect that the new tubulin binding ligands described herein may prove to be enhanced vascular targeting agents once functionalized as diphosphates. The syntheses of these compounds will parallel the methodology described in the various synthetic schemes delineated within this application and will be readily apparent to persons skilled in the art. A representative synthesis is illustrated in
FIG. 13 . - IC50 values for tubulin polymerization were determined according to a previously described procedure (Bai et al, Cancer Research, 1996). Purified tubulin is obtained from bovine brain cells as described in Hamel and Lin (Hamel and Lin, Biochemistry, 1984). Various amounts of inhibitor were preincubated for 15 minutes at 37° C. with purified tubulin. After the incubation period, the reaction was cooled and GTP was added to induce tubulin polymerization. Polymerization was then monitored in a Gilford spectrophotometer at 350 nm. The final reaction mixtures (0.25 ml) contained 1.5 mg/ml tubulin, 0.6 mg/ml microtubule-associated proteins (MAPs), 0.5 mM GTP, 0.5 mM MgCl2, 4% DMSO and 0.1M 4-morpholineethanesulfonate buffer (MES, pH 6.4). IC50 is the amount of inhibitor needed to inhibit
tubulin polymerization 50% with respect to the amount of inhibition that occurs in the absence of inhibitor.TABLE 1 In Vitro Inhibition of Tubulin Polymerization. Compound IC50 (μM) CA-4 1.2 (±0.02) Oxi-com 141, 29 1-2 Oxi- com 142, 310.5-1.0 Oxi-com 143, 32 Inactive (>40) Oxi-com 148, 27 1 Oxi-com 156, 26 1-4 Oxi-com 196, 37 0.5-1 Oxi- com 199, 50Inactive (>40) - a) Human Cancer Cell Lines
- The activity of several compounds were tested against a variety of cell lines derived from human tumors, using an assay system similar to a procedure previously described (Monks et al, J. Natl. Cancer Inst., 1991). Briefly, the cell suspensions, diluted according to the particular cell type and the expected target cell density (5,000-40,000 cells per well based on cell growth characteristics), were added by pipet (100 μl) to 96-well microtiter plates. Inoculates were allowed a preincubation time of 24-28 hours at 37° C. for stabilization. Incubation with the inhibitor compounds lasted for 48 hours in 5% CO2 atmosphere and 100% humidity. Determination of cell growth was performed by in situ fixation of cells, followed by staining with a protein-binding dye sulforhodamine B (SRB), which binds to the basic amino acids of cellular macromolecules. The solubilized stain was measured spectrophotometrically.
- Several compounds were evaluated for cytotoxic activity against human P388 leukemia cell lines. The effective dose or ED50 value (defined as the effective dosage required to inhibit 50% of cell growth) was measured. These and additional compounds were evaluated in terms of growth inhibitory activity against several other human cancer cell lines including: central nervous system (“CNS”, SF-295), pancreas (BXPC-3), non-small cell lung cancer (“lung-NSC”, NCI-H460), breast (MCF-7), colon (KM20L2), and prostate (DU-145). The results are described in Table 2 below. The growth inhibition GI50 (defined as the dosage required to inhibit tumor cell growth by 50%) is listed for each cell line.
TABLE 2 In vitro Cytotoxicity against Human Cancer Cell Lines ED50 (ug/ml) for P-388 GI50 (μg/ml) for Cell Line Compound Cell Line SF-295 BXPC-3 NCI-H460 MCF-7 KM20L2 DU-145 Oxi-com 156, 26 0.13 0.043 0.67 0.16 0.11 0.38 Oxi-com 141, 29 0.0033 0.0054 0.0038 0.0010 0.0032 0.0037 Oxi- com 142, 310.034 0.0029 0.0034 0.0026 <0.001 0.0027 0.0038 Oxi-com 143, 32 20.4 2.2 2.0 3.4 3.0 2.5 2.8 Oxi-com 158, 36 5.4 1.8 3.2 1.5 2.6 3.4 Oci-com 196, 37 0.00175 0.00012 0.10 0.0032 <0.0001 0.27 0.00040 Oxi- com 197, 430.00182 0.0033 0.28 0.011 0.0045 0.33 0.0055
b) Murine Cancer Cell Lines - The following compounds were tested for in vitro antiproliferative activity against the murine hemangioendothelioma MHEC-5T cell line using a standard MTT assay (see Mosman, J. Immunol. Methods, 1983). In actively proliferating cells, an increase in MTT conversion is spectrophotometrically quantified by the reduction of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) to the insoluble formazan dye by enzymes associated with metabolic activity. A compound with growth inhibitory activity will cause a reduction in dye formation relative to cells exposed to a vehicle control. The IC50 value (defined as the amount of compound required to inhibit growth of 50% of cells with respect to a control treatment) for each compound was determined at one hour and five days at (see Table 3 below).
TABLE 3 In vitro Cytotoxicity against Murine cancer cell lines Compound IC50 (μM) at 1 hour IC50 (μM) at 5 days Oxi-com 196, 37 0.11 0.004 Oxi- com 197, 430.10 0.003 Oxi- com 199, 50>44.8 >44.8 Oxi-com 200, 49 >50 16.2 Oxi-com 224, 47 0.4 0.003 Oxi-com 225, 48 0.4 0.005 Oxi-com 229, 33 >44 >1.4 Oxi-com 238, 38 14.0 0.04 Oxi-com 239, 44 2.4 0.06 Oxi-com 240, 39 8.0 0.03 Oxi-com 241, 45 2.5 0.08 Oxi-com 243, 46 20. 0.30 - The antivascular effects of the C-5 dihydronaphthalene phosphate prodrug Oxi-
com 197, 43 was assessed in tumor-bearing mice using a Fluorescent Bead Assay. A MHEC-5T hemangioendothelioma tumor model was established by subcutaneous injection of 0.5×106 cultured transformed cell murine myocardial vascular endothelial cell line (“MHEC5-T”) cells into the right flank of Fox Chase CB-17 Severe Combined Immunodeficient (“SCID”) mice. When transplanted tumors reached a size of 500 mm3 (a size without development of necrosis), the mice received a single intraperitoneal (i.p.) injection of saline control or compound at doses ranging from 3.2 to 25 mg/kg. At 24 hours post-treatment, mice were injected intravenously with 0.25 ml of diluted FluoSphere beads (1:6 in physiological saline) in the tail vein, sacrificed after 3 minutes, and tumor was excised for cryosectioning. Tumor cryosections at a thickness of 8 um were directly examined using quantitative fluorescent microscopy. Blood vessels were indicated by blue fluorescence from injected beads. For quantification, image analysis of 3 sections from three tumors treated in each group were examined and vascular shutdown was expressed as vessel area (mm2) per tumor tissue area (mm2) as a percentage of the control (“% VAPM”) and as vessel number per tumor tissue area (mm2) as a percentage of the control (“% VNPM”). The results as shown in Table 11 indicate a clear dose-dependent effect of the agent on tumor blood flow as indicated by the reduction in blood vessel number and vessel area. Administration of a 25 mg/kg dose of Oxi-com 197 was particularly effective, causing a 90% reduction in tumor vessel number relative to the control.TABLE 4 Vascular Targeting Activity of Oxi- com 197 prodrugDose (mg/kg) % VAPM % VNPM 0 100 ± 13.5 100 ± 10.8 3.2 101.6 ± 36.6 89.1 ± 25.6 6.3 65.4 ± 4.9 66.5 ± 0.5 12.5 32.2 ± 6.8 55.5 ± 0.8 25 13.0 ± 5.0 10.4 ± 6.3 - Additional compounds of the present invention were tested for antivascular effects at two dosages (100 mg/kg and 10 mg/kg) using the same Fluorescent Bead Assay as in the previous experiment. The results are summarized in Table 5 below.
TABLE 5 Vascular Targeting Activity of Aroyl dihydronaphthalene and Aroyl Napthalene phosphate prodrugs % VAPM at 100 mg/kg % VAPM at 10 mg/kg Compound dose dose Oxi-com 224, 47 46 17 Oxi-com 225, 48 60 35 - The antitumor activity of C-5 dihydronaphthalene phosphate prodrug, Oxi-
com 197, was assessed in tumor-bearing mice by measuring its effects on tumor volume in comparison with CA4P. A human breast adenocarcinoma model was established by subcutaneous injection of cultured MDA-MB-231 cells in Fox Chase CB-17 SCID mice. When the average tumor size reached 50-100 mm3, mice were randomly divided into several groups (n=10) with no significant difference in body weight and tumor size. Mice were administered CA4P or Oxi-com 197 in saline carrier at doses of 25, 50 or 100mg/kg by daily intraperitoneal (i.p.) injection for 5 consecutive days (Q1×5). Saline carrier only was used as the control treatment. OnDay 15 3, 7, 10, 13, 17 and 23, tumors were excised from animals in each treatment group (n=2) and measured by width and length. Tumor volume was calculated according to the following formula: Length×Width2×0.4. The dosage effects of Oxi-com 197 is illustrated inFIG. 14 . Administration of 25, 50, and 100 mg/kg doses of the drug significantly inhibited tumor growth relative to control treatment. C-5-DHN-P was also observed to have enhanced antitumor activity relative to CA4P. - All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. For instance, in addition to the various metal salts described for the phosphates and phosphoramidates, any appropriate metal or non-metal cation and, in fact, any appropriately related salt construct can be employed without departing from the spirit and scope of the invention. For therapeutic and/or prophylactic anti-tumor purposes, the prodrugs of the present invention would be administered at a dosage of from about 5 mg/m2 to about 100 mg/m2 while intravascular infusion of the prodrug is preferred other modes of parenteral topical or enteral administration are usable under certain conditions.
- The present invention also involves uses of the novel compounds described in manners relating to their useful effects on tubulin polymerization and abnormal vasculature. Certainly a method for inhibiting tubulin polymerization is a part of the present invention. This involves contacting a tubulin containing system with an effective amount of a compound described in the present invention. This tubulin containing system may be in a tumor cell, thereby inhibiting neoplastic disease by administering an effective amount of a compound of the present invention. Patients may thus be treated. In cases of cancer treatment, it is believed that many neoplasias such as leukemia, lung cancer, colon cancer, thyroid cancer, CNS, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancers may be effectively treated by the administration of an effective amounts of the compounds described in the present invention. Pharmaceutical preparations may be prepared by mixing the compounds of the present invention with a pharmaceutically acceptable carrier. This may be in tablet or intravascular form. In one important aspect, macular degeneration, and related diseases of the eye where vascularization is involved, may be treated by a method comprising administering an effective amount of a compound described in the present invention. Psoriasis may also be treated by administering an effective amount of the compound of the present invention. Likewise, any disease or condition caused or enhanced by undesired vascularization may be treated by administering an effective amount of a compound of the present invention.
- In addition to their tumor-selective vascular targeting and destruction capabilities, it is contemplated that all the compounds of the present invention have potential application in the treatment of other diseases where the issue of vascularization is of great significance. Representative examples of these diseases include: diseases associated with ocular neovascularization (corneal and retinal), psoriasis and arthritis. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
- The following citations are incorporated in pertinent part by reference herein for the reasons cited.
- 1. Bai, R.; Schwartz, R. E.; Kepler, J. A.; Pettit, G. R.; Hamel, E., Characterization of the Interaction of Cryptophycin with Tubulin: Binding in the Vinca Domain, Competitive Inhibition of
Dolastatin 10 Binding, and an Unusual Aggregation Reaction, Cancer Res., 1996, 56, 4398-4406. - 2. Boger, D. L.; Curran, T. T., Synthesis of the Lower Subunit of Rhizoxin, J. Org. Chem. 1992, 57, 2235.
- 3. Chaplin D J, Pettit G R, Hill S A. Anti-vascular approaches to solid tumor therapy: Evaluation of combretastatin A4 phophate. Anticancer Res., 1999; 19:189-196.
- 4. Chavan, A. J.; Richardson, S. K.; Kim, H.; Haley, B. E.; Watt, D. S., Forskolin Photoaffinity Probes for the Evaluation of Tubulin Binding Sites, Bioconjugate Chem. 1993, 4, 268.
- 5. Cortese, F.; Bhattacharyya, B.; Wolff, J., Podophyllotoxin as a Probe for the Colchicine Binding Site of Tubulin, J. Biol. Chem., 1977, 252, 1134.
- 6. Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin, C. M.; Hamel, E. Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivatives as Potential Anticancer Agents That Inhibit Tubulin Polymerization, J. Med. Chem. 1991, 34, 2579.
- 7. Dark, G. G., Hill, S. A., Prise, V. G., Tozer, G. M., Pettit, G. R., Chaplin, D. J., Combretastatin A-4, an Agent That Displays Potent and Selective Toxicity Toward Tumor Vasculature, Cancer Res., 1997, 57, 1829-1834.
- 8. Davis P D, Dougherty G J, Blakey D C, Galbraith S M, Tozer G M, Holder A L, Naylor M A, Nolan J, Stratford M R, Chaplin D J, Hill S A. ZD6126: A Novel Vascular-targeting Agent that causes selective destruction of tumor vasculature. Cancer Research. 2002. 62(24): 7247-53.
- 9. Dorr, R. T.; Dvorakova, K.; Snead, K.; Alberts, D. S.; Salmon, S. E.; Pettit, G. R., Antitumor Activity of Combretastatin A4 Phosphate, a Natural Product Tubulin Inhibitor, Invest. New Drugs, 1996, 14, 131.
- 10. Floyd. L. J.; Barnes, L. D.; Williams, R. F., Photoaffinity Labeling of Tubulin with (2-Nitro-4-azidophenyl)deacetylcolchicine: Direct Evidence for Two Colchicine Binding Sites, Biochemistry, 1989, 28, 8515.
- 11. Gerwick, W. H.; Proteau, P. J.; Nagle, D. G.; Hamel, E.; Blokhin, A.; Slate, D. L., Structure of Curacin A, a Novel Antimitotic, Antiproliferative, and Brine Shrimp Toxic Natural Product from the Marine Cyanobacterium Lyngbya majuscula, J. Org. Chem. 1994, 59, 1243.
- 12. Hahn, K. M.; Hastie, S. B.; Sundberg, R. J., Synthesis and Evaluation of 2-Diazo-3,3,3-trifluoropropanoyl Derivatives of Colchicine and Podophyllotoxin as Photoaffinity Labels: Reactivity, Photochemistry, and Tubulin Binding, Photochem. Photobiol. 1992, 55, 17.
- 13. Hamel, E., Antimitotic Natural Products and Their Interactions with Tubulin, Medicinal Research Reviews, 1996, 16, 207.
- 14. Hamel, E.; Lin, C. M., Separation of Active Tubulin and Microtubule-Associated Proteins by Ultracentrifugation and Isolation of a Component Causing the Formation of Microtubule Bundles, Biochemistry, 1984, 23, 4173-4184.
- 15. Hammonds, T. R.; Denyer, S. P.; Jackson, D. E.; Irving, W. L., Studies To Show That With Podophyllotoxin the Early Replicative Stages of Herpes Simplex Virus Type I Depend Upon Functional Cytoplasmic Microtubules, J. Med. Microbiol., 1996, 45, 167.
- 16. Iyer S, Chaplin D J, Rosenthal D S, et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 1998; 58:4510-4514.
- 17. Jiang, J. B.; Hesson, D. P.; Dusak, B. A.; Dexter, D. L.; Kang, G. J.; Hamel, E., Synthesis and Biological Evaluation of 2-Styrylquinazolin-4(3H)-ones, a New Class of Antimitotic Anticancer Agents Which Inhibit Tubulin Polymerization, J. Med. Chem. 1990, 33, 1721.
- 18. Kanthou C, Tozer G M. The tumor vascular targeting agent CA4P induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood. 2002. 99(6):2060-9.
- 19. Kingston, D. G. I.; Samaranayake, G.; Ivey, C. A., The Chemistry of Taxol, a Clinically Useful Anticancer Agent, J. Nat. Prod. 1990, 53, 1.
- 20. Kobayashi, S.; Nakada, M.; Ohno, M., Synthetic Study on an Antitumor Antibiotic Rhizoxin by Using an Enzymatic Process on Prochiral beta-Substituted Glutarates, Pure Appl. Chem. 1992, 64, 1121.
- 21. Kobayashi, S.; Nakada, M.; Ohno, M., Synthetic Study on an Antitumor Antibiotic Rhizoxin by Using an Enzymatic Process on Prochiral beta-Substituted Glutarates Indian J. Chem., Sect. B. 1993, 32B, 159.
- 22. Lavielle, G.; Havtefaye, P.; Schaeffer, C.; Boutin, J. A.; Cudennec, C. A.; Pierre, A., New α-Amino Phosphonic Acid Derivatives of Vinblastine: Chemistry and Antitumor Activity, J. Med. Chem. 1991, 34, 1998.
- 23. Lejeune P, Hodge T G, Vrignaud, Bissery M-C. In vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. Proceedings of the AACR. ABSTRACT#781. 2002, 43: 156.
- 24. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E., Antimitotic Natural Products Combretastatin A-4 and Combretastatin A-2: Studies on the Mechanism of Their Inhibition of the Binding of Colchicine to Tubulin, Biochemistry 1989, 28, 6984.
- 25. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich; Campbell; Mayo; Boyd, M., Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines, J. Natl. Cancer Inst., 1991, 83, 757-766.
- 26. Mossman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods, 1983, 16, 195-200.
- 27. Nakada, M.; Kobayashi, S.; Iwasaki, S.; Ohno, M., The First Total Synthesis of the Antitumor Macrolide Rhizoxin: Synthesis of the Key Building Blocks, Tetrahedron Lett. 1993, 34, 1035.
- 28. Nicolaou, K. C., Winssinger, N., Pastor, J., Ninkovic, S., Sarabia, F., He, Y., Vourloumis, D., Yang, Z., Oi, T., Giannakakou, P., Hamel, E., Synthesis of Epothilones A and B in Solid and Solution Phase, Nature, 1997, 387, 268-272.
- 29. Nogales, E., Wolf, S. G., and Downing, K. H., Structure of the α,β Tubulin Dimer by Electron Crystallography, Nature, 1998, 391, 199-203.
- 30. Owellen, R. J.; Hartke, C. A.; Kickerson, R. M.; Hains, F. O., Inhibition of Tubulin-Microtubule Polymerization by Drugs of the Vinca Alkaloid Class, Cancer Res. 1976, 36, 1499.
- 31. Pettit, G. R.; Rhodes, M. R., Antineoplastic agents 393. Synthesis of the trans-isomer of CA4P. Anti-Cancer Drug Des., 1998, 13, 183.
- 32. Pettit, G. R., Srirangam, J. K., Barkoczy, J., Williams, M. D., Boyd, M. R., Hamel, E., Pettit, R. K., Hogan F., Bai, R., Chapuis, J. C., McAllister, S. C., Schmidt, J. M., Antineoplastic Agents 365:
Dolastatin 10 SAR Probes, Anti-Cancer Drug Des., 1998, 13, 243-277. - 33. Pettit, G. R., Toki, B., Herald, D. L., Verdier-Pinard, P., Boyd, M. R., Hamel, E., Pettit, R. K., Antineoplastic Agents 379. Synthesis of Phenstatin Phosphate, J. Med. Chem., 1998, 41, 1688-1695.
- 34. Pettit, G. R.; Cragg, G. M.; Singh, S. B., Antineoplastic agents, 122. Constituents of Combretum caffrum, J. Nat. Prod. 1987, 50, 386.
- 35. Pettit, G. R., Kamano, Y., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B., Bontems, R. J., The Isolation and Structure of a Remarkable Marine Animal Antineoplastic Constituent:
Dolastatin 10, J. Am. Chem. Soc., 1987, 109, 6883-6885. - 36. Pettit, G. R.; Singh, S. B.; Cragg, G. M., Synthesis of Natural (−)-Combretastatin, J. Org. Chem. 1985, 50, 3404.
- 37. Pettit, G. R.; Cragg, G. M.; Herald, D. L.; Schmidt, J. M.; Lohavanijaya, P., Isolation and Structure of combretastatin, Can, J. Chem. 1982, 60, 1374.
- 38. Rao, A. V. R.; Bhanu, M. N.; Sharma, G. V. M., Studies Directed Towards the Total Synthesis of Rhizoxin: Stereoselective Synthesis of C-12 to C-18 Segment, Tetrahedron Lett. 1993, 34, 707.
- 39. Rao, S.; Horwitz, S. B.; Ringel, I., Direct Photoaffinity Labeling of Tubulin with Taxol, J. Natl. Cancer Inst., 1992, 84, 785.
- 40. Rao, A. V. R.; Sharma, G. V. M.; Bhanu, M. N., Radical Mediated Enantioselective Construction of C-1 to C-9 Segment of Rhizoxin, Tetrahedron Lett. 1992, 33, 3907.
- 41. Safa, A. R.; Hamel, E.; Felsted, R. L., Photoaffinity Labeling of Tubulin Subunits with a Photoactive Analog of Vinblastine,
Biochemistry 1987, 26, 97. - 42. Sawada, T.; Kato, Y.; Kobayashi, H.; Hashimoto, Y.; Watanabe, T.; Sugiyama, Y.; Iwasaki, S., A Fluorescent Probe and a Photoaffinity Labeling Reagent to Study the Binding Site of Maytansine and Rhizoxin on Tubulin, Bioconjugate Chem., 1993, 4, 284. 31.
- 43. Sawada, T.; Kobayashi, H.; Hashimoto, Y.; Iwasaki, S., Identification of the Fragment Photoaffinity-labeled with Azidodansyl-rhizoxin as Met-363-Lys-379 on beta-Tubulin, Biochem. Pharmacol. 1993, 45, 1387.
- 44. Schiff, P. B.; Fant, J.; Horwitz, S. B., Promotion of Microtubule Assembly In Vitro by Taxol, Nature, 1979, 277, 665.
- 45. Staretz, M. E.; Hastie, S. B., Synthesis, Photochemical Reactions, and Tubulin Binding of Novel Photoaffinity Labeling Derivatives of Colchicine, J. Org. Chem. 1993, 58, 1589.
- 46. Swindell, C. S.; Krauss, N. E.; Horwitz, S. B.; Ringel, I., Biologically Active Taxol Analogs with Deleted A-ring Side Chain Substituents and Variable C-2 C′Configurations, J. Med. Chem. 1991, 34, 1176. (d) Parness, J.; Horwitz, S. B., Taxol Binds to Polymerized Tubulin In Vitro, J. Cell Biol. 1981, 91, 479.
- 47. Tozer, G. M.; Prise, V. E.; Wilson, J.; Locke, R. J.; Vojnovic, B.; Stratford, M. R. L.; Dennis, M. F.; Chaplin, D. J., Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues. Cancer Res., 1999, 59, 1626.
- 48. Williams, R. F.; Mumford, C. L.; Williams, G. A.; Floyd, L. J.; Aivaliotis, M. J.; Martinez, R. A.; Robinson, A. K.; Barnes, L. D., A Photoaffinity Derivative of Colchicine: 6-(4′-Azido-2′-nitrophenylamino)hexanoyldeacetylcolchicine: Photolabeling and Location of the Colchicine-binding Site on the alpha-subunit of Tubulin, J. Biol. Chem. 1985, 260, 13794.
- 49. Zhang, X.; Smith, C. D., Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance, Molecular Pharmacology, 1996, 49, 288.
Claims (43)
1. A method for treating a vascular proliferative disorder in an animal comprising administering to an animal an effective amount of a compound of formula I:
wherein R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H, OH, amine, lower alkoxy, phosphate, phosphoramidate, or amino acid acyl group;
X is a single covalent bond or a carbonyl group, and
Y is optionally H or OH.
2. The method of claim 1 , wherein the vascular proliferative disorder is characterized by the presence of nonmalignant proliferating vasculature.
3. The method of claim 2 , wherein the malignant proliferating vasculature is associated with a tumor or other neoplastic disease.
4. The method of claim 2 , wherein the vascular proliferative disorder is characterized by the presence of nonmalignant proliferating vasculature.
5. The method of claim 4 , wherein the nonmalignant proliferating vasculature is associated with an ocular disease selected from the group comprising wet or age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, diabetic macular edema, uveitis, or corneal neovascularization.
6. The method of claim 4 , wherein the nonmalignant proliferating vasculature is associated with a nonocular disease state such as psoriasis, rheumatoid arthritis, atheroma, restenosis, Kaposi's sarcoma, haemangioma, and in general, inflammatory diseases characterized by vascular proliferation.
7. The method of claim 1 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is lower alkoxy.
8. The method of claim 1 , wherein R4 is OMe.
9. The method of claim 1 , wherein X is a single bond.
10. The method of claim 1 , wherein X is a carbonyl.
11. The method of claim 1 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is phosphate.
13. A method for selectively reducing the flow of blood to at least a portion of a neoplastic region thereby causing substantial necrosis of tissue in the neoplastic region without substantial necrosis of tissue in adjoining regions by administering a compound of formula I:
wherein R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H, OH, amine, lower alkoxy, phosphate, phosphoramidate, or amino acid acyl group;
X is a single covalent bond or a carbonyl, and
Y is optionally H or OH.
14. The method of claim 13 , wherein the reduction in tumor blood flow is reversible such that normal tumor blood flow is restored following cessation of treatment.
15. The method of claim 13 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is alkoxy.
16. The method of claim 13 , wherein R4 is OMe.
17. The method of claim 13 , wherein X is a single bond.
18. The method of claim 13 , wherein X is a carbonyl.
19. The method of claim 13 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is phosphate.
21. A method for treating neoplastic disease in an animal comprising administering to an animal an antiproliferative amount of a compound of formula I:
wherein R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H, OH, amine, lower alkoxy, phosphate, phosphoramidate, or amino acid acyl group;
X is a single covalent bond or a carbonyl, and
Y is optionally H or OH.
22. The method of claim 21 , wherein the reduction in tumor blood flow is reversible such that normal tumor blood flow is restored following cessation of treatment.
23. The method of claim 21 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is lower alkoxy.
24. The method of claim 21 , wherein R4 is OMe.
25. The method of claim 21 , wherein X is a single bond.
26. The method of claim 21 , wherein X is a carbonyl.
27. The method of claim 21 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is phosphate.
29. A method for inhibiting tubulin polymerization by contacting a tubulin-containing system with a compound of formula I:
wherein R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H, OH, amine, lower alkoxy, phosphate, phosphoramidate, or amino acid acyl group;
X is single covalent bond or a carbonyl group, and
Y is optionally H or OH.
30. The method of claim 29 , wherein said system is a tumor cell.
31. The method of claim 29 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is lower alkoxy.
32. The method of claim 29 , wherein R4 is OMe.
33. The method of claim 29 , wherein X is a single bond.
34. The method of claim 29 , wherein X is a carbonyl.
35. The method of claim 29 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is phosphate.
37. A pharmaceutical formulation containing a compound of formula I in a pharmaceutically suitable carrier:
wherein R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of H, OH, amine, lower alkoxy, phosphate, phosphoramidate, or amino acid acyl group;
X is a single covalent bond or a carbonyl, and
Y is optionally H or OH.
38. The method of claim 37 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is lower alkoxy.
39. The method of claim 37 , wherein R4 is OMe.
40. The method of claim 37 , wherein X is a single bond.
41. The method of claim 37 , wherein X is a carbonyl.
42. The method of claim 37 , wherein at least one of R2, R3, R4, R5, R6, R7, or R8 is phosphate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/359,095 US20060142252A1 (en) | 1999-02-18 | 2006-02-21 | Tubulin binding agents and corresponding prodrug constructs |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12047899P | 1999-02-18 | 1999-02-18 | |
US09/505,402 US6538038B1 (en) | 1999-02-18 | 2000-02-16 | Compositions and methods for use in targeting vascular destruction |
US18829500P | 2000-03-10 | 2000-03-10 | |
US09/804,280 US6593374B2 (en) | 2000-03-10 | 2001-03-12 | Tubulin binding ligands and corresponding prodrug constructs |
US10/218,833 US6956054B2 (en) | 1999-02-18 | 2002-08-14 | Compositions and methods for use in targeting vascular destruction |
US10/404,525 US7001926B2 (en) | 2000-03-10 | 2003-04-01 | Tubulin binding agents and corresponding prodrug constructs |
US11/359,095 US20060142252A1 (en) | 1999-02-18 | 2006-02-21 | Tubulin binding agents and corresponding prodrug constructs |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/218,833 Continuation-In-Part US6956054B2 (en) | 1999-02-18 | 2002-08-14 | Compositions and methods for use in targeting vascular destruction |
US10/404,525 Continuation US7001926B2 (en) | 1999-02-18 | 2003-04-01 | Tubulin binding agents and corresponding prodrug constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060142252A1 true US20060142252A1 (en) | 2006-06-29 |
Family
ID=33130475
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/404,525 Expired - Fee Related US7001926B2 (en) | 1999-02-18 | 2003-04-01 | Tubulin binding agents and corresponding prodrug constructs |
US11/359,095 Abandoned US20060142252A1 (en) | 1999-02-18 | 2006-02-21 | Tubulin binding agents and corresponding prodrug constructs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/404,525 Expired - Fee Related US7001926B2 (en) | 1999-02-18 | 2003-04-01 | Tubulin binding agents and corresponding prodrug constructs |
Country Status (2)
Country | Link |
---|---|
US (2) | US7001926B2 (en) |
WO (1) | WO2004087061A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021129827A1 (en) * | 2019-12-27 | 2021-07-01 | 南京明德新药研发有限公司 | Benzo fused ring-based compound |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088918B2 (en) * | 2004-08-11 | 2012-01-03 | Williamsburg Holdings Llc | Noncardiotoxic pharmaceutical compounds |
WO2006138427A2 (en) * | 2005-06-14 | 2006-12-28 | Baylor University | Combretastatin analogs with tubulin binding activity |
AU2006259261B2 (en) * | 2005-06-16 | 2013-06-13 | Myrexis, Inc. | Pharmaceutical compositions and use thereof |
WO2007137196A2 (en) * | 2006-05-19 | 2007-11-29 | Threshold Pharmaceuticals, Inc. | Tubulin binding anti cancer compounds and prodrugs thereof |
AU2008236995A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Dosages and methods for the treatment of cancer |
EP2144888A4 (en) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | Methods for treating cancer |
EP2144886A4 (en) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | Method of treating melanoma |
JP2010523696A (en) * | 2007-04-10 | 2010-07-15 | ミリアド ファーマシューティカルズ, インコーポレイテッド | How to treat brain tumors |
WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
EP3836910A1 (en) * | 2018-08-17 | 2021-06-23 | Baylor University | Benzosuberene analogues and related compounds with activity as anticancer agents |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
US5532382A (en) * | 1995-03-13 | 1996-07-02 | Eli Lilly And Company | Benzothiophenes substituted at the 3-carbonyl |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
US5886025A (en) * | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
US5952350A (en) * | 1996-10-24 | 1999-09-14 | Eli Lilly And Company | Naphthyl compounds and compositions, as estrogen receptor binding agents |
US5958916A (en) * | 1996-08-29 | 1999-09-28 | Eli Lilly And Company | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods |
US6162930A (en) * | 1998-03-06 | 2000-12-19 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3210434A (en) * | 1962-12-14 | 1965-10-05 | Ashland Oil Inc | Production of phenylnapthalene |
US3538227A (en) * | 1967-01-30 | 1970-11-03 | Ciba Geigy Corp | Tricyclic phenoxy-acid and ester hypocholesterolemic compositions |
US3515746A (en) * | 1967-01-30 | 1970-06-02 | Ciba Geigy Corp | Tricyclic acids |
US3754934A (en) * | 1970-09-25 | 1973-08-28 | Int Flavors & Fragrances Inc | Flavoring and fragrance compositions and processes |
US3879432A (en) * | 1972-12-18 | 1975-04-22 | Itt | Plicatamides |
US6545027B1 (en) | 1995-06-07 | 2003-04-08 | Eli Lilly And Company | Methods of modulating NF-kB transcription factor |
ZA988954B (en) | 1997-10-02 | 1999-04-12 | Snow Brand Milk Products Co Ltd | Novel dihydronaphthalene compound and production process of the same |
CA2407967C (en) | 2000-03-10 | 2010-10-05 | Baylor University | Tubulin binding ligands and corresponding prodrug constructs |
IL152082A0 (en) | 2000-04-07 | 2003-05-29 | Pfizer Prod Inc | Estrogen agonist/antagonist metabolites |
US6943183B2 (en) | 2000-04-17 | 2005-09-13 | Pfizer Inc | 5-substituted tetralones as inhibitors of ras farnesyl transferase |
US6773702B2 (en) * | 2000-12-26 | 2004-08-10 | Oxigene, Inc. | Use of combretastatin A4 and its prodrugs as an immune enhancing therapy |
AUPR283801A0 (en) | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
-
2003
- 2003-04-01 US US10/404,525 patent/US7001926B2/en not_active Expired - Fee Related
-
2004
- 2004-03-26 WO PCT/US2004/009417 patent/WO2004087061A2/en active Application Filing
-
2006
- 2006-02-21 US US11/359,095 patent/US20060142252A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
US5532382A (en) * | 1995-03-13 | 1996-07-02 | Eli Lilly And Company | Benzothiophenes substituted at the 3-carbonyl |
US5958916A (en) * | 1996-08-29 | 1999-09-28 | Eli Lilly And Company | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods |
US5952350A (en) * | 1996-10-24 | 1999-09-14 | Eli Lilly And Company | Naphthyl compounds and compositions, as estrogen receptor binding agents |
US5886025A (en) * | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
US6162930A (en) * | 1998-03-06 | 2000-12-19 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
US6350777B2 (en) * | 1999-12-03 | 2002-02-26 | Baylor University | Description anti-mitotic agents which inhibit tubulin polymerization |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021129827A1 (en) * | 2019-12-27 | 2021-07-01 | 南京明德新药研发有限公司 | Benzo fused ring-based compound |
Also Published As
Publication number | Publication date |
---|---|
US20040043969A1 (en) | 2004-03-04 |
US7001926B2 (en) | 2006-02-21 |
WO2004087061A3 (en) | 2005-03-17 |
WO2004087061A2 (en) | 2004-10-14 |
WO2004087061B1 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060142252A1 (en) | Tubulin binding agents and corresponding prodrug constructs | |
US20070082872A1 (en) | Indole-containing compounds with anti-tubulin and vascular targeting activity | |
US8394859B2 (en) | Combretastatin analogs with tubulin binding activity | |
USRE45907E1 (en) | Functionalized stilbene derivatives as improved vascular targeting agents | |
EP1751128B1 (en) | Chromene-derivatives with anti-tubulin and vascular targeting activity | |
EP1263763B1 (en) | Tubulin binding ligands | |
US7091240B2 (en) | Tubulin binding ligands and corresponding prodrug constructs | |
WO2004099139A1 (en) | Indole-containing compounds with anti-tubulin and vascular targeting activity | |
US8198302B2 (en) | Compositions and methods with enhanced therapeutic activity | |
ES2349746T3 (en) | COMPOUNDS DERIVED FROM THE CHROMENE WITH ANTI-TIBULIN AND VASCULAR DIANA ACTIVITY. | |
AU2002361579A1 (en) | Functionalized stilbene derivatives as improved vascular targeting agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |